[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 13984
6. Tien AH, Xu L, Helgason CD: Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res; 2005 Apr 1;65(7):2947-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered immunity accompanies disease progression in a mouse model of prostate dysplasia.
  • In this study, we sought to determine the nature of, and cellular mechanisms underlying, changes in immune status during disease progression in a transgenic mouse model of prostate dysplasia.
  • Functional studies confirmed a role for CD4(+)CD25(+) regulatory T cells in suppressing T-cell proliferation as well as regulating the growth of transplanted prostate tumor cells.
  • In addition, our studies show for the first time that anti-CD25 antibody treatment reduces, but does not prevent, tumor growth in a transgenic mouse model of prostate dysplasia.
  • These studies thus provide the impetus for development of specific and effective strategies to deplete regulatory T cells, or suppress their function, as an alternative or adjunct strategy for reducing tumor growth.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805298.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Receptors, Interleukin-2
  •  go-up   go-down


7. Engiz O, Balci S, Unsal M, Ozer S, Oguz KK, Aktas D: 31 cases with oculoauriculovertebral dysplasia (Goldenhar syndrome): clinical, neuroradiologic, audiologic and cytogenetic findings. Genet Couns; 2007;18(3):277-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 31 cases with oculoauriculovertebral dysplasia (Goldenhar syndrome): clinical, neuroradiologic, audiologic and cytogenetic findings.
  • Goldenhar syndrome (GS) or oculoauriculovertebral dysplasia (OAVD) is characterized by pre-auricular skin tags, microtia, facial asymmetry, ocular abnormalities and vertebral anomalies of different size and shape.
  • OAVD patients present with different morphologic features and systemic manifestations.

  • Genetic Alliance. consumer health - Goldenhar Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019368.001).
  • [ISSN] 1015-8146
  • [Journal-full-title] Genetic counseling (Geneva, Switzerland)
  • [ISO-abbreviation] Genet. Couns.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


8. Yang YF, Li H, Xu XQ, Diao YT, Fang XQ, Wang Y, Zhao DL, Wu K, Li HQ: An expression of squamous cell carcinoma antigen 2 in peripheral blood within the different stages of esophageal carcinogenesis. Dis Esophagus; 2008;21(5):395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The malignant transformation of esophageal mucosa is a progressive process, which includes basal cell hyperplasia, dysplasia, carcinoma in situ, and invasive esophageal squamous cell carcinoma (ESCC).
  • The subjects consisted of 50 patients with basal cell hyperplasia, 50 patients with dysplasia, 50 patients with ESCC (12 carcinoma in situ, 38 carcinoma in invasive stage), and 50 controls who were pathologically diagnosed to be normal and whose esophageal mucosa were stained brown by iodine.
  • By using the band intensity ratios of SCCA2 to beta-actin, with a positive cut-off value of > or = 0.4, the positive rates of the SCCA2 mRNA expression in peripheral blood were found to be 82% (41/50), 60% (30/50), 48% (24/50), and 36% (18/50) in the cancer, dysplasia, basal cell hyperplasia, and control groups, respectively.
  • The positive rate of the cancer group was significantly different from the three other groups (P < 0.05), and there was also a significant difference in the SCCA2 mRNA expression between the dysplasia group and the control group (chi(2)=5.769, P= 0.016).
  • In the multinomial logistic regression analysis, the odds ratios (ORs) were 1.71 [95% confidence interval (95% CI), 0.73-3.99] in the basal cell hyperplasia group, 2.77 (95% CI, 1.14-6.71) in the dysplasia group, and 7.87 (95% CI, 2.88-21.55) in the cancer group after being adjusted for age, gender, smoking index, drinking index, and family history of esophageal cancer.
  • By using a positive cut-off value of > or = 0.4, the testing sensitivities in the basal cell hyperplasia, dysplasia, and cancer groups were found to be 48%, 60%, and 82%, respectively, with the same testing specificity at 64%.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125792.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  •  go-up   go-down


9. Kasamatsu E, Bravo LE, Bravo JC, Aguirre-García J, Flores-Luna L, Nunes-Velloso Mdel C, Hernández-Suárez G: [Reproducibility of histopathologic diagnosis of precursor lesions of gastric carcinoma in three Latin American countries]. Salud Publica Mex; 2010 Sep-Oct;52(5):386-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The concordance (k) between pathologists with experience and those without was poor for the diagnosis of atrophic gastritis (k=0.04 to 0.12) and dysplasia (k=0.11 to 0.05), and good for the diagnosis of intestinal metaplasia (k=0.52 to 0.58).
  • Supervision of pathologists without experience by those with experience remarkably improved the concordance in the diagnosis of atrophic gastritis (k=0.65) and intestinal metaplasia (k=0.91), and to a lesser degree, of dysplasia (k=0.28).
  • The concordance among experts before and after the consensus meeting showed no variation in the diagnosis of atrophic gastritis (k=0.57); the concordance varied from good to excellent in the diagnosis of intestinal metaplasia (k=0.67 to 0.81) and from poor to good in that of dysplasia (k=0.18 to 0.66).
  • CONCLUSION: The greatest differences arose in the diagnosis of chronic atrophic gastritis and dysplasia.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21031244.001).
  • [ISSN] 1606-7916
  • [Journal-full-title] Salud pública de México
  • [ISO-abbreviation] Salud Publica Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


10. Somford MP, Bolder SB, Gardeniers JW, Slooff TJ, Schreurs BW: Favorable survival of acetabular reconstruction with bone impaction grafting in dysplastic hips. Clin Orthop Relat Res; 2008 Feb;466(2):359-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable survival of acetabular reconstruction with bone impaction grafting in dysplastic hips.
  • Acetabular bone loss hampers implantation of a total hip arthroplasty in patients with developmental dysplasia of the hip.
  • The bone impaction grafting technique in combination with a cemented cup is an effective technique for developmental dysplasia of the hip with favorable long-term results.

  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Orthop Scand. 1984 Dec;55(6):593-6 [6395620.001]
  • [Cites] Clin Orthop Relat Res. 1979 Jun;(141):17-27 [477100.001]
  • [Cites] Orthop Clin North Am. 1988 Jul;19(3):477-89 [3269211.001]
  • [Cites] Clin Orthop Relat Res. 1989 Jun;(243):126-37 [2721052.001]
  • [Cites] J Bone Joint Surg Am. 1991 Sep;73(8):1123-42 [1890115.001]
  • [Cites] Orthop Clin North Am. 1993 Oct;24(4):663-5 [8414432.001]
  • [Cites] Clin Orthop Relat Res. 1994 Jul;(304):165-71 [8020209.001]
  • [Cites] J Bone Joint Surg Br. 1996 Mar;78(2):270-5 [8666640.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):683-92 [8642024.001]
  • [Cites] J Bone Joint Surg Am. 1997 Feb;79(2):159-68 [9052535.001]
  • [Cites] Orthop Clin North Am. 1998 Apr;29(2):277-95 [9553573.001]
  • [Cites] J Bone Joint Surg Br. 1999 Sep;81(5):843-5 [10530847.001]
  • [Cites] J Bone Joint Surg Am. 2004 Nov;86-A(11):2385-92 [15523007.001]
  • [Cites] J Bone Joint Surg Br. 2005 Jan;87(1):16-20 [15686231.001]
  • [Cites] J Bone Joint Surg Am. 2005 Feb;87(2):280-5 [15687148.001]
  • [Cites] J Bone Joint Surg Am. 2005 Feb;87(2):339-45 [15687157.001]
  • [Cites] Acta Orthop. 2005 Apr;76(2):149-58 [16097538.001]
  • [Cites] J Arthroplasty. 2005 Jun;20(4):492-8 [16124966.001]
  • [Cites] J Arthroplasty. 2005 Sep;20(6):698-702 [16139704.001]
  • [Cites] J Bone Joint Surg Am. 2005 Dec;87(12):2619-25 [16322610.001]
  • [Cites] J Arthroplasty. 2005 Dec;20(8):1021-8 [16376258.001]
  • [Cites] J Arthroplasty. 2005 Dec;20(8):1029-36 [16376259.001]
  • [Cites] J Bone Joint Surg Am. 2006 Jan;88(1):71-9 [16391251.001]
  • [Cites] J Bone Joint Surg Am. 2006 Jan;88(1):80-91 [16391252.001]
  • [Cites] J Bone Joint Surg Br. 2006 Feb;88(2):173-8 [16434519.001]
  • [Cites] J Bone Joint Surg Am. 2006 Feb;88(2):387-94 [16452752.001]
  • [Cites] Int Orthop. 2006 Feb;30(1):21-5 [16362384.001]
  • [Cites] J Bone Joint Surg Am. 2006 Oct;88(10):2231-6 [17015601.001]
  • [Cites] J Arthroplasty. 2007 Jan;22(1):89-94 [17197314.001]
  • [Cites] Clin Orthop Relat Res. 2001 Dec;(393):202-15 [11764350.001]
  • [Cites] Clin Orthop Relat Res. 2001 Dec;(393):216-27 [11764351.001]
  • [Cites] J Arthroplasty. 2001 Dec;16(8 Suppl 1):164-9 [11742470.001]
  • [Cites] J Arthroplasty. 2001 Dec;16(8 Suppl 1):170-6 [11742471.001]
  • [Cites] Clin Orthop Relat Res. 2002 Mar;(396):131-41 [11859236.001]
  • [Cites] J Arthroplasty. 2002 Jun;17(4 Suppl 1):162-6 [12068430.001]
  • [Cites] J Arthroplasty. 2003 Jun;18(4):401-10 [12820080.001]
  • [Cites] J Bone Joint Surg Am. 2004 Feb;86-A(2):242-50 [14960667.001]
  • [Cites] J Bone Joint Surg Am. 2004 Feb;86-A(2):312-9 [14960676.001]
  • [Cites] J Bone Joint Surg Am. 2004 Mar;86-A Suppl 1:11-7 [14996917.001]
  • [Cites] J Bone Joint Surg Br. 2004 May;86(4):492-7 [15174541.001]
  • [Cites] Int Orthop. 2004 Aug;28(4):202-5 [15118840.001]
  • [Cites] J Bone Joint Surg Am. 1969 Jun;51(4):737-55 [5783851.001]
  • [Cites] Clin Orthop Relat Res. 1976 Nov-Dec;(121):20-32 [991504.001]
  • [Cites] J Bone Joint Surg Am. 1979 Jan;61(1):15-23 [365863.001]
  • [Cites] Clin Orthop Relat Res. 1983 Oct;(179):214-22 [6617020.001]
  • [Cites] Clin Orthop Relat Res. 1987 May;(218):136-41 [3568473.001]
  • (PMID = 18196418.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2505129
  •  go-up   go-down


11. Fattori R, Tricoci P, Russo V, Lovato L, Bacchi-Reggiani L, Gavelli G, Branzi A, Boriani G: Quantification of fatty tissue mass by magnetic resonance imaging in arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol; 2005 Mar;16(3):256-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of fatty tissue mass by magnetic resonance imaging in arrhythmogenic right ventricular dysplasia.
  • INTRODUCTION: Arrhythmogenic right ventricular dysplasia (ARVD) is a heart muscle disorder in which the pathological substrate is a fatty or fibro-fatty replacement of the right ventricular (RV) myocardium.
  • METHODS AND RESULTS: Magnetic resonance imaging (MRI) studies were performed in 10 patients with arrhythmogenic right ventricular dysplasia and in 24 matched controls in order to assess right ventricular epicardial/intramyocardial fatty tissue mass, RV myocardial mass, and RV functional parameters.
  • [MeSH-major] Adipose Tissue / pathology. Arrhythmogenic Right Ventricular Dysplasia / diagnosis. Magnetic Resonance Imaging. Ventricular Function, Right

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817082.001).
  • [ISSN] 1045-3873
  • [Journal-full-title] Journal of cardiovascular electrophysiology
  • [ISO-abbreviation] J. Cardiovasc. Electrophysiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Beer TA, Chidgey LK, Wright TW: Dysplasia epiphysealis hemimelica of the carpus. J Surg Orthop Adv; 2005;14(1):42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplasia epiphysealis hemimelica of the carpus.
  • Dysplasia epiphysealis hemimelica (Trevor's disease) is a rare developmental disorder characterized by unilateral, asymmetrical proliferation of epiphyseal cartilage.
  • Three cases, the largest series to date, involving dysplasia epiphysealis hemimelica of the carpus, are discussed here.

  • Genetic Alliance. consumer health - Dysplasia Epiphysealis Hemimelica.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15766442.001).
  • [ISSN] 1548-825X
  • [Journal-full-title] Journal of surgical orthopaedic advances
  • [ISO-abbreviation] J Surg Orthop Adv
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. H'mida D, Gribaa M, Yacoubi T, Chaieb A, Adala L, Elghezal H, Saad A: Placental mesenchymal dysplasia with beckwith-wiedemann syndrome fetus in the context of biparental and androgenic cell lines. Placenta; 2008 May;29(5):454-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental mesenchymal dysplasia with beckwith-wiedemann syndrome fetus in the context of biparental and androgenic cell lines.
  • Placental mesenchymal dysplasia (PMD) is a distinct placental disorder that may coexist with a normal fetus.

  • Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342934.001).
  • [ISSN] 0143-4004
  • [Journal-full-title] Placenta
  • [ISO-abbreviation] Placenta
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens
  •  go-up   go-down


1
Advertisement
4. Chang LC, Oelschlager BK, Quiroga E, Parra JD, Mulligan M, Wood DE, Pellegrini CA: Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surveillance for Barrett's esophagus. J Gastrointest Surg; 2006 Mar;10(3):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surveillance for Barrett's esophagus.
  • Endoscopic surveillance is recommended for patients with Barrett's esophagus to detect high-grade dysplasia (HGD) or cancer.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 Aug;91(8):943-7 [15286953.001]
  • [Cites] J Clin Epidemiol. 1998 Nov;51(11):1159-65 [9817133.001]
  • [Cites] Lancet Oncol. 2003 Aug;4(8):481-8 [12901962.001]
  • [Cites] Br J Surg. 2003 Sep;90(9):1120-8 [12945080.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):137-41 [14760658.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3089-96 [11095322.001]
  • [Cites] J Gastrointest Surg. 2000 Mar-Apr;4(2):131-4 [10885959.001]
  • [Cites] Dis Esophagus. 2004;17(1):10-26 [15209736.001]
  • [Cites] Am J Gastroenterol. 1989 Mar;84(3):220-3 [2919577.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2004 Summer;16(2):152-9 [15197690.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Dig Dis Sci. 2003 Aug;48(8):1537-41 [12924649.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • (PMID = 16504878.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Capelle LG, Haringsma J, de Vries AC, Steyerberg EW, Biermann K, van Dekken H, Kuipers EJ: Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. Dig Dis Sci; 2010 Dec;55(12):3442-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy.
  • Narrow band imaging (NBI) may enhance the accuracy of endoscopic surveillance of intestinal metaplasia (IM) and dysplasia.We aimed to compare the yield of NBI to white light endoscopy (WLE) in the surveillance of patients with (IMa)and dysplasia.Methods Patients with previously identified gastric IM or dysplasia underwent a surveillance endoscopy.
  • Dysplasia was detected in seven patients by WLE and NBI and in two patients by random biopsies only.
  • Nine endoscopically detected lesions demonstrated dysplasia: eight were detected by WLE and NBI, one was detected by NBI only.The sensitivity, specificity, positive and negative predictive values for detection of premalignant lesions were 71, 58,65 and 65% for NBI and 51, 67, 62 and 55% for WLE,respectively.Conclusions NBI increases the diagnostic yield for detection of advanced premalignant gastric lesions compared to routine WLE.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Gastroenterol. 2008 Sep;24(5):631-7 [19122507.001]
  • [Cites] Gastrointest Endosc. 2010 Jun;71(7):1150-8 [20381801.001]
  • [Cites] Heart. 2000 Feb;83(2):236 [10744442.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Oct;15 Suppl:G49-57 [11100994.001]
  • [Cites] Gut. 2002 Jul;51(1):130-1 [12077106.001]
  • [Cites] Endoscopy. 2002 Oct;34(10):772-7 [12244497.001]
  • [Cites] Gut. 2003 Jan;52(1):28-33 [12477755.001]
  • [Cites] Endoscopy. 2003 Nov;35(11):946-50 [14606018.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):191-8 [14745391.001]
  • [Cites] Endoscopy. 2004 Feb;36(2):165-9 [14765314.001]
  • [Cites] Am J Gastroenterol. 1979 Apr;71(4):376-9 [453128.001]
  • [Cites] Endoscopy. 1984 May;16(3):101-4 [6734532.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):162-6 [10228782.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1080-4 [15578298.001]
  • [Cites] Gut. 2005 Apr;54(4):461-8 [15753528.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1179-86 [16230072.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1807-8 [16285989.001]
  • [Cites] Endoscopy. 2005 Dec;37(12):1215-9 [16329020.001]
  • [Cites] J Gastroenterol. 2006 Apr;41(4):332-8 [16741612.001]
  • [Cites] Endoscopy. 2006 Aug;38(8):819-24 [17001572.001]
  • [Cites] Helicobacter. 2007 Feb;12(1):1-15 [17241295.001]
  • [Cites] Endoscopy. 2007 Mar;39(3):202-7 [17273960.001]
  • [Cites] Endoscopy. 2007 Nov;39(11):937-41 [18008201.001]
  • [Cites] Gastric Cancer. 2008;11(1):15-21; discussion 21-2 [18373173.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):945-52 [18395075.001]
  • [Cites] Gastrointest Endosc. 2008 May;67(6):843-53 [18440377.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Oct 1;28(7):854-67 [18637003.001]
  • [Cites] Endoscopy. 2009 Apr;41(4):310-5 [19340733.001]
  • [Cites] Gastrointest Endosc. 2009 Jul;70(1):18-25 [19249770.001]
  • (PMID = 20393882.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tanaka JL, Ono E, Filho EM, Castilho JC, Moraes LC, Moraes ME: Cleidocranial dysplasia: importance of radiographic images in diagnosis of the condition. J Oral Sci; 2006 Sep;48(3):161-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cleidocranial dysplasia: importance of radiographic images in diagnosis of the condition.
  • Cleidocranial dysplasia (CCD) is a rare syndrome usually caused by an autosomal dominant gene, although 40% of cases of CCD appear spontaneously with no apparent genetic cause.
  • [MeSH-major] Cleidocranial Dysplasia / radiography

  • Genetic Alliance. consumer health - Cleidocranial Dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023750.001).
  • [ISSN] 1343-4934
  • [Journal-full-title] Journal of oral science
  • [ISO-abbreviation] J Oral Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Ievleva NF, Chizhova GV, Tsygankov VI: [Cytometric characterization of the cell nucleus and nucleolus apparatus in dysplasia and exocervical cancer of the cervix uteri]. Klin Lab Diagn; 2006 May;(5):55-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytometric characterization of the cell nucleus and nucleolus apparatus in dysplasia and exocervical cancer of the cervix uteri].
  • The morphometric parameters of the nucleonucleolar apparatus of the intact stratified squamous epithelium of the cervix uteri, dysplasias, and exocervical cancer were studied by computed morphometry of 50% silver nitrate solution-stained cytological specimens in order to study nucleolar organizers.
  • It was shown that dysplastic changes and malignant transformation were marked by a progressive increase in the values of morphometric parameters of its nucleonucleolar apparatus.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Nucleolus / pathology. Cell Nucleus / pathology. Nucleolus Organizer Region / pathology. Uterine Cervical Dysplasia / pathology. Uterine Cervical Neoplasms / pathology


18. Cardoso CL, Prado RF, Taveira LA: Macroscopic and microscopic study of tissue response to oral antiseptics and its influence on carcinigenesis. J Appl Oral Sci; 2005 Sep;13(3):286-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three serial sections of each tongue were evaluated, and characteristics related to epithelial hyperkeratinization, atrophy, hyperplasia and dysplasia were organized in tables.
  • Despite the observation for moderate dysplasia in one case in the Anapyon 20 week group, the further results were very similar to the control group (saline solution), eliminating the need of comparative statistical tests.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878032.001).
  • [ISSN] 1678-7757
  • [Journal-full-title] Journal of applied oral science : revista FOB
  • [ISO-abbreviation] J Appl Oral Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


19. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, Cooper K, Walker D, McWilliams A, Liu G, Szabo E, Brody J, Massion PP, Lenburg ME, Lam S, Bild AH, Spira A: Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med; 2010 Apr 7;2(26):26ra25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed a significant increase in a genomic signature of phosphatidylinositol 3-kinase (PI3K) pathway activation in the cytologically normal bronchial airway of smokers with lung cancer and smokers with dysplastic lesions, suggesting that PI3K is activated in the proximal airway before tumorigenesis.
  • Further, PI3K activity is decreased in the airway of high-risk smokers who had significant regression of dysplasia after treatment with the chemopreventive agent myo-inositol, and myo-inositol inhibits the PI3K pathway in vitro.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Nov 16;19(48):5471-6 [11114724.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16156-61 [12461184.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):226-30 [12754511.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3716-23 [12839964.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):105-14 [14693816.001]
  • [Cites] Oncogene. 2004 Mar 4;23(9):1754-65 [14755253.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10143-8 [15210990.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5131-6 [15297416.001]
  • [Cites] Cancer. 1970 Jan;25(1):92-104 [5410320.001]
  • [Cites] Nature. 1985 May 16-22;315(6016):239-42 [2987699.001]
  • [Cites] Science. 1989 Oct 27;246(4929):491-4 [2554494.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2873-8 [9230193.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1366-73 [9308707.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2133-7 [9329980.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5221-5 [9393738.001]
  • [Cites] Oncogene. 1998 Jul 30;17(4):449-54 [9696038.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2025-34 [10473082.001]
  • [Cites] World J Gastroenterol. 2005 Jan 14;11(2):285-8 [15633233.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93 [15731348.001]
  • [Cites] Biochem Soc Trans. 2005 Apr;33(Pt 2):350-3 [15787604.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] Int J Oncol. 2005 Aug;27(2):481-8 [16010431.001]
  • [Cites] Z Gastroenterol. 2005 Oct;43(10):1133-9 [16220453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15948-53 [16249342.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9623-7 [16266979.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):921-9 [16341083.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 [16341064.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Science. 2006 May 26;312(5777):1175-8 [16728632.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1526-31 [16896044.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17402-7 [17090670.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):294-7 [17229957.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2226-38 [17332353.001]
  • [Cites] Nat Med. 2007 Mar;13(3):361-6 [17334370.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Neoplasia. 2007 May;9(5):443-54 [17534450.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Aug;63(2):172-82 [17540577.001]
  • [Cites] Breast Cancer Res Treat. 2007 Nov;105(3):319-26 [17268817.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4 [18077471.001]
  • [Cites] Genome Biol. 2007;8(9):R201 [17894889.001]
  • [Cites] J Cell Sci. 2008 Feb 1;121(Pt 3):249-53 [18216329.001]
  • [Cites] PLoS One. 2008;3(2):e1651 [18297132.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):564-70 [18385730.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6913-21 [18757405.001]
  • [Cites] Oncogene. 2008 Sep 18;27(41):5486-96 [18794883.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):56-64 [19138936.001]
  • [Cites] Sci Signal. 2009;2(55):ra4 [19176518.001]
  • [Cites] Breast Cancer Res. 2008;10(6):R101 [19055754.001]
  • [Cites] Mol Cancer. 2009;8:9 [19228372.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):370-6 [19336734.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7603-11 [19738040.001]
  • (PMID = 20375364.001).
  • [ISSN] 1946-6242
  • [Journal-full-title] Science translational medicine
  • [ISO-abbreviation] Sci Transl Med
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE12815
  • [Grant] United States / NIEHS NIH HHS / ES / U01 ES016035; United States / NCI NIH HHS / CA / R01 CA124640; United States / NCI NIH HHS / CA / CA90949; United States / NIEHS NIH HHS / ES / U01ES016035; United States / NCI NIH HHS / CA / P50 CA090949; United States / NCI NIH HHS / CA / R01CA124640
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 4L6452S749 / Inositol; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS471724; NLM/ PMC3694402
  •  go-up   go-down


20. Podowski M, Calvi CL, Cheadle C, Tuder RM, Biswals S, Neptune ER: Complex integration of matrix, oxidative stress, and apoptosis in genetic emphysema. Am J Pathol; 2009 Jul;175(1):84-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alveolar enlargement, which is characteristic of bronchopulmonary dysplasia, congenital matrix disorders, and cigarette smoke-induced emphysema, is thought to result from enhanced inflammation and ensuing excessive matrix proteolysis.
  • Although there is recent evidence that cell death and oxidative stress punctuate these diseases, the mechanistic link between abnormal lung extracellular matrix and alveolar enlargement is lacking.
  • These data establish that an abnormal extracellular matrix without overt elastolysis is sufficient to confer susceptibility to postnatal normoxia, reminiscent of bronchopulmonary dysplasia.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 2005 Dec;33(6):555-64 [16151053.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G1137-47 [16037546.001]
  • [Cites] Exp Eye Res. 2006 Aug;83(2):380-9 [16626700.001]
  • [Cites] Proc Am Thorac Soc. 2006 Nov;3(8):668-72 [17065371.001]
  • [Cites] Proc Am Thorac Soc. 2006 Nov;3(8):713-7 [17065379.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Apr;36(4):409-17 [17079780.001]
  • [Cites] Biochem Soc Trans. 2007 Apr;35(Pt 2):284-7 [17371261.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1211-8 [17209140.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Apr;38(4):393-400 [17975176.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Sep;23(3):320-6 [10970822.001]
  • [Cites] J Invest Dermatol. 2001 Jan;116(1):136-43 [11168809.001]
  • [Cites] Arthritis Rheum. 2001 Mar;44(3):712-22 [11263787.001]
  • [Cites] Nature. 2002 Jan 10;415(6868):168-71 [11805834.001]
  • [Cites] Nature. 2002 Jan 10;415(6868):171-5 [11805835.001]
  • [Cites] Restor Neurol Neurosci. 2001;18(2-3):127-35 [11847435.001]
  • [Cites] Trends Pharmacol Sci. 2002 Mar;23(3):122-9 [11879679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3800-5 [11891315.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 May;32(5):367-72 [15837726.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L739-49 [15964899.001]
  • [Cites] Trends Genet. 2002 May;18(5):265-71 [12047952.001]
  • [Cites] Science. 2002 Jul 12;297(5579):259-63 [12114629.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):407-11 [12598898.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 May;284(5):L727-37 [12676763.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):73-81 [12707371.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Jul;29(1):88-97 [12600822.001]
  • [Cites] Free Radic Biol Med. 2003 Aug 1;35(3):236-56 [12885586.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Nov;29(5):562-70 [12748058.001]
  • [Cites] Antioxid Redox Signal. 2004 Feb;6(1):155-67 [14713347.001]
  • [Cites] Nat Genet. 2004 Feb;36(2):178-82 [14745449.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13705-10 [14736885.001]
  • [Cites] Appl Bioinformatics. 2003;2(4):209-17 [15130792.001]
  • [Cites] Am J Pathol. 1976 Mar;82(3):493-512 [176891.001]
  • [Cites] Am Rev Respir Dis. 1981 Jun;123(6):680-5 [7271067.001]
  • [Cites] Am Rev Respir Dis. 1984 May;129(5):850-5 [6562869.001]
  • [Cites] J Clin Invest. 1985 Oct;76(4):1297-305 [4056033.001]
  • [Cites] J Cell Biol. 1986 Dec;103(6 Pt 1):2499-509 [3536967.001]
  • [Cites] Am Rev Respir Dis. 1989 Jan;139(1):226-32 [2912343.001]
  • [Cites] Exp Mol Pathol. 1989 Jun;50(3):398-410 [2721656.001]
  • [Cites] Exp Mol Pathol. 1989 Aug;51(1):18-30 [2767216.001]
  • [Cites] Am Rev Respir Dis. 1991 Jun;143(6):1365-8 [1646582.001]
  • [Cites] Exp Mol Pathol. 1992 Apr;56(2):163-72 [1587342.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7915-22 [8367443.001]
  • [Cites] Biochem J. 1994 Apr 1;299 ( Pt 1):237-45 [8166647.001]
  • [Cites] Eur J Immunol. 1994 Jun;24(6):1463-6 [7911425.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6264-8 [7603981.001]
  • [Cites] Adv Pharmacol. 1997;38:205-27 [8895810.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Jun;18(6):786-93 [9618383.001]
  • [Cites] Free Radic Biol Med. 1999 Sep;27(5-6):612-6 [10490282.001]
  • [Cites] Circ Res. 2004 Nov 26;95(11):1067-74 [15528465.001]
  • [Cites] Neuroscientist. 2005 Feb;11(1):50-62 [15632278.001]
  • [Cites] Neurochem Res. 2005 Jan;30(1):105-11 [15756938.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Jun;34(6):688-94 [16439805.001]
  • (PMID = 19541933.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01-HL081205; United States / NHLBI NIH HHS / HL / R01-HL066554; United States / NHLBI NIH HHS / HL / R01 HL081205; United States / NHLBI NIH HHS / HL / R01 HL085312; United States / NHLBI NIH HHS / HL / R01 HL066554; United States / NHLBI NIH HHS / HL / KO8-HL067980; United States / NHLBI NIH HHS / HL / K08 HL074945; United States / NHLBI NIH HHS / HL / R01-HL085312; United States / NHLBI NIH HHS / HL / K08 HL067980; United States / NHLBI NIH HHS / HL / P50HL074945
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Microfilament Proteins; 0 / fibrillin
  • [Other-IDs] NLM/ PMC2708797
  •  go-up   go-down


21. Amamra N, Touzet S, Colin C, Ponchon T: Impact of guidelines for endoscopy in patients with Barrett's esophagus: a multifaceted interventional study. Gastroenterol Clin Biol; 2009 Jun-Jul;33(6-7):470-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Main outcome measures were based on biopsies for diagnosis, surveillance intervals and management of patients with high-grade dysplasia.
  • Management of high-grade dysplasia increased from 16.0 to 24.3% (p<0.01).

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443156.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


22. Quatresooz P, Xhauflaire-Uhoda E, Piérard-Franchimont C, Piérard GE: Epidermal field carcinogenesis in bald-headed: An attempt at finetuning early non-invasive detection. Oncol Rep; 2009 May;21(5):1313-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this latter case histology and morphometry disclosed keratinocyte dysplasia.
  • It is suggested that the presently described condition may be associated with or indicative for actinic field carcinogenesis and incipient keratinocyte dysplasia.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Aging.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19360309.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


23. Loro LL, Johannessen AC, Vintermyr OK: Loss of BCL-2 in the progression of oral cancer is not attributable to mutations. J Clin Pathol; 2005 Nov;58(11):1157-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There have been reports of loss of BCL-2 in basal cells of oral epithelial dysplasia (OED) and in oral squamous cell carcinoma (OSCC), and suppression of BAX in poorly differentiated OSCC.
  • CONCLUSIONS: No mutations were found that could explain loss of BCL-2 in oral dysplasia and carcinoma.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 11;18(47):6589-96 [10597263.001]
  • [Cites] Oncogene. 1991 Mar;6(3):455-60 [2011401.001]
  • [Cites] J Oral Pathol Med. 2000 Feb;29(2):63-9 [10718401.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5A):2855-60 [11062693.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6318-25 [11103792.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):15598-608 [11278953.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):691-8 [12167422.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1107-15 [1648447.001]
  • [Cites] Blood. 1992 Jan 1;79(1):229-37 [1339299.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3686-97 [8388542.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4978-86 [8402688.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2352-60 [8139540.001]
  • [Cites] Nature. 1994 May 26;369(6478):321-3 [8183370.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3131-5 [8205530.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Mar;79(3):321-9 [7621010.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jun;88(2):136-40 [8640722.001]
  • [Cites] Science. 1997 Feb 14;275(5302):967-9 [9020077.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1129-32 [9027314.001]
  • [Cites] FEBS Lett. 1997 Apr 7;406(1-2):31-2 [9109380.001]
  • [Cites] EMBO J. 1997 Aug 1;16(15):4628-38 [9303307.001]
  • [Cites] Cell. 1997 Nov 14;91(4):479-89 [9390557.001]
  • [Cites] Science. 1997 Dec 12;278(5345):1966-8 [9395403.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2991-7 [9531611.001]
  • [Cites] Hum Genet. 1998 Oct;103(4):435-40 [9856487.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2034-7 [10232581.001]
  • [Cites] Hum Pathol. 1999 Sep;30(9):1097-105 [10492046.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1051-60 [12213734.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):355-7 [12379854.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7765-75 [12420213.001]
  • [Cites] J Oral Pathol Med. 2003 Mar;32(3):125-38 [12581382.001]
  • [Cites] Oral Oncol. 2003 Apr;39(3):213-21 [12618193.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):747-51 [14970847.001]
  • [Cites] J Immunol Methods. 1989 Dec 20;125(1-2):279-85 [2558138.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6597-604 [10597264.001]
  • (PMID = 16254104.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / DNA, Neoplasm; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / bcl-2-Associated X Protein
  • [Other-IDs] NLM/ PMC1770776
  •  go-up   go-down


24. Barahona-Dussault C, Benito B, Campuzano O, Iglesias A, Leung TL, Robb L, Talajic M, Brugada R: Role of genetic testing in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Clin Genet; 2010 Jan;77(1):37-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of genetic testing in arrhythmogenic right ventricular cardiomyopathy/dysplasia.
  • In a cohort of patients with confirmed or suspected arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), genetic testing is useful in confirming the diagnosis, particularly in individuals who do not completely fulfil Task Force criteria for the disease, thereby also enabling the adoption of preventive measures in family members.
  • [MeSH-major] Arrhythmogenic Right Ventricular Dysplasia / genetics. Genetic Testing


25. Ng AP, Wei A, Bhurani D, Chapple P, Feleppa F, Juneja S: The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica; 2006 Jul;91(7):972-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accurate quantification of plasma cells in bone marrow samples is essential for the diagnosis, classification and prognosis of plasma-cell dyscrasias.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818287.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Coloring Agents; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


26. Xiang H, Chen HX, Yu XX, King MA, Roper SN: Reduced excitatory drive in interneurons in an animal model of cortical dysplasia. J Neurophysiol; 2006 Aug;96(2):569-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced excitatory drive in interneurons in an animal model of cortical dysplasia.
  • Cortical dysplasia (CD) is strongly associated with epilepsy.
  • Enhanced excitability in dysplastic neuronal networks is believed to contribute to epileptogenesis, but the underlying mechanisms for the hyperexcitability are poorly understood.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16641376.001).
  • [ISSN] 0022-3077
  • [Journal-full-title] Journal of neurophysiology
  • [ISO-abbreviation] J. Neurophysiol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS-35651
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Hansen AR, Barnés CM, Folkman J, McElrath TF: Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr; 2010 Apr;156(4):532-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal preeclampsia predicts the development of bronchopulmonary dysplasia.
  • OBJECTIVE: To test the hypothesis that exposure to preeclampsia is associated with an increased risk of bronchopulmonary dysplasia (BPD).
  • This has possible implications for the prevention of BPD with proangiogenic agents, such as vascular endothelial growth factor.
  • [MeSH-major] Bronchopulmonary Dysplasia / etiology. Maternal Exposure / adverse effects. Pre-Eclampsia. Prenatal Exposure Delayed Effects / etiology

  • Genetic Alliance. consumer health - Preeclampsia.
  • Genetic Alliance. consumer health - Bronchopulmonary Dysplasia.
  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • [CommentIn] J Pediatr. 2010 Apr;156(4):521-3 [20303437.001]
  • (PMID = 20004912.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Niizuma S, Nakahama H, Inenaga T, Yoshihara F, Nakamura S, Yoshii M, Kamide K, Horio T, Kawano Y: Asymptomatic renal infarction, due to fibromuscular dysplasia, in a young woman with 11 years of follow-up. Clin Exp Nephrol; 2005 Jun;9(2):170-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic renal infarction, due to fibromuscular dysplasia, in a young woman with 11 years of follow-up.
  • We report a 27-year-old woman with renovascular hypertension, renal infarction, and hepatic artery aneurysm due to fibromuscular dysplasia.
  • This case suggests the need for long-term and periodical follow-up of patients with fibromuscular dysplasia.
  • [MeSH-major] Fibromuscular Dysplasia / complications. Hypertension, Renal / pathology. Infarction / pathology. Kidney / pathology. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Fibromuscular Dysplasia.
  • Genetic Alliance. consumer health - Renal dysplasia.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vasc Surg. 1999 Jan;29(1):140-9 [9882798.001]
  • [Cites] Dig Dis Sci. 1982 Jan;27(1):73-9 [6461535.001]
  • [Cites] Arch Pathol Lab Med. 1992 Mar;116(3):238-41 [1536608.001]
  • [Cites] J Vasc Interv Radiol. 1992 Feb;3(1):111-7 [1540711.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):184-9 [10873889.001]
  • [Cites] Mod Pathol. 1995 Apr;8(3):287-94 [7617656.001]
  • [Cites] Am J Med. 2003 Jun 15;114(9):729-35 [12829199.001]
  • [Cites] J Vasc Surg. 1988 Mar;7(3):449-53 [3258042.001]
  • [Cites] Cardiovasc Intervent Radiol. 1997 Sep-Oct;20(5):383-6 [9271651.001]
  • [Cites] J Rheumatol. 1998 Oct;25(10 ):2015-8 [9779860.001]
  • [Cites] Urology. 1990 Jan;35(1):73-5 [2296823.001]
  • [Cites] J Vasc Surg. 2001 Jan;33(1):188-90 [11137943.001]
  • (PMID = 15980954.001).
  • [ISSN] 1342-1751
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Gingelmaier A, Grubert T, Kaestner R, Mylonas I, Weissenbacher T, Bergauer F, Barthell L, Friese K: High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women. Anticancer Res; 2007 Jul-Aug;27(4A):1795-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women.
  • AIM: A) evaluation of the recurrence of cervical dysplasia after surgical treatment and of the rate of HPV persistence of HIV-infected women and b) the influence of antiretroviral therapy on the recurrence.
  • PATIENTS AND METHODS: In a retrospective analysis, the follow-up data of HIV-positive women visiting our outpatient clinic regarding results of cervical cytology, cervical HPV detection, cervical biopsy, patient history of dysplasia and antiretroviral therapy were assessed.
  • Overall, 157/388 had cervical dysplasia and 70 needed surgery.
  • DISCUSSION: The recurrence of cervical dysplasia in HIV-positive women after surgical treatment was found to be very high as was the associated long-term persistence of HPV-infection.
  • HPV persistence represented an excellent marker for relapsing cervical dysplasia.
  • [MeSH-major] HIV Infections / complications. Papillomavirus Infections / epidemiology. Tumor Virus Infections / epidemiology. Uterine Cervical Dysplasia / complications. Uterine Cervical Dysplasia / pathology


30. Polizzi A, Pavone P, Iannetti P, Manfré L, Ruggieri M: Septo-optic dysplasia complex: a heterogeneous malformation syndrome. Pediatr Neurol; 2006 Jan;34(1):66-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Septo-optic dysplasia complex: a heterogeneous malformation syndrome.
  • Septo-optic dysplasia is defined by a variable combination of dysgenesis of midline brain structures including optic nerve hypoplasia and hypothalamic-pituitary dysfunction often associated with a wide variety of brain malformations of cortical development.
  • Despite recent demonstration of the possible pathogenic role of HESX1/Hesx1 gene (a homeobox gene important for development of prosencephalon), the etiology of most cases of septo-optic dysplasia still remains unclear.
  • This report describes eight children (4 males, 4 females; age 2 to 17 years) with septo-optic dysplasia who manifested dysmorphic features (involving not only the midline facial structures) and a spectrum of additional clinical and imaging features including autism, facial hemangioma, and holoprosencephaly.
  • Based on the extreme variability of the clinical and imaging phenotypes hereby observed, on literature review, and on septo-optic dysplasia animal models, this study confirmed that the phenotypic heterogeneity in septo-optic dysplasia is high.
  • (2) septo-optic dysplasia should be recategorized as an heterogeneous malformation syndrome (septo-optic dysplasia complex) (encompassing multiple brain, endocrine, and systemic anomalies) rather than a single precisely defined entity.
  • [MeSH-major] Abnormalities, Multiple / genetics. Abnormalities, Multiple / pathology. Brain / pathology. Homeodomain Proteins / genetics. Septo-Optic Dysplasia / genetics. Septo-Optic Dysplasia / pathology

  • Genetic Alliance. consumer health - Septo-optic dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376284.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HESX1 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


31. Krejci P, Salazar L, Kashiwada TA, Chlebova K, Salasova A, Thompson LM, Bryja V, Kozubik A, Wilcox WR: Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS One; 2008;3(12):e3961
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage.
  • Activating mutations in FGFR3 tyrosine kinase cause several forms of human skeletal dysplasia.
  • Here, we analyzed STAT1 activation by the N540K, G380R, R248C, Y373C, K650M and K650E-FGFR3 mutants associated with skeletal dysplasias.
  • Similarly, in RCS chondrocytes, HeLa, and 293T cellular environments, only K650M and K650E-FGFR3 caused strong STAT1 activation.
  • Thus the ability to activate STAT1 appears restricted to the K650M and K650E-FGFR3 mutants, which however account for only a small minority of the FGFR3-related skeletal dysplasia cases.


32. Kellinghaus C, Möddel G, Shigeto H, Ying Z, Jacobsson B, Gonzalez-Martinez J, Burrier C, Janigro D, Najm IM: Dissociation between in vitro and in vivo epileptogenicity in a rat model of cortical dysplasia. Epileptic Disord; 2007 Mar;9(1):11-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissociation between in vitro and in vivo epileptogenicity in a rat model of cortical dysplasia.
  • CONCLUSION: Neocortical freeze lesions induced in newborn rat pups show histological characteristics reminiscent of human cortical dysplasia.

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Seizures.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17307707.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 1R21 NS42354; United States / NINDS NIH HHS / NS / K08 NS02046
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] WM5Z385K7T / Pentylenetetrazole
  •  go-up   go-down


33. Tippett SR: Returning to sports after periacetabular osteotomy for developmental dysplasia of the hip. N Am J Sports Phys Ther; 2006 Feb;1(1):32-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Returning to sports after periacetabular osteotomy for developmental dysplasia of the hip.
  • BACKGROUND: A periacetabular osteotomy,indicated for adults or adolescents requiring correction of congruency and containment of the femoral head, is a common surgical procedure to address developmental dysplasia of the hip.
  • OBJECTIVES: To describe developmental hip dysplasia, a surgical procedure performed to address the condition, as well as therapeutic exercise and functional progression principles utilized to return a patient to tennis following periacetabular osteotomy.
  • CASE DESCRIPTION: The patient was a 14 year-old female who underwent a Ganz periacetabular osteotomy of the right pelvis due to developmental dysplasia of the hip.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phys Ther. 1999 Apr;79(4):371-83 [10201543.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jun;(363):64-72 [10379306.001]
  • [Cites] J Am Acad Orthop Surg. 1999 Sep-Oct;7(5):325-37 [10504359.001]
  • [Cites] Clin Orthop Relat Res. 2004 Jan;(418):9-17 [15043086.001]
  • [Cites] Surg Radiol Anat. 1998;20(3):153-9 [9706672.001]
  • [Cites] Clin Orthop Relat Res. 2004 Jan;(418):74-80 [15043096.001]
  • [Cites] Clin Orthop Relat Res. 2004 Dec;(429):182-7 [15577485.001]
  • [Cites] J Bone Joint Surg Am. 1977 Dec;59(8):1082-91 [591540.001]
  • [Cites] Clin Orthop Relat Res. 2004 Jan;(418):18-22 [15043087.001]
  • (PMID = 21522198.001).
  • [ISSN] 1558-6162
  • [Journal-full-title] North American journal of sports physical therapy : NAJSPT
  • [ISO-abbreviation] N Am J Sports Phys Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2953281
  •  go-up   go-down


34. Comhaire FH, Criel AC, Dassy CA, Guévar PG, Snaps FR: Precision, reproducibility, and clinical usefulness of measuring the Norberg angle by means of computerized image analysis. Am J Vet Res; 2009 Feb;70(2):228-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SAMPLE POPULATION: 1,182 consecutive radiographs of hip joints of various breeds of dogs assessed for hip dysplasia and 72 radiographs of hip joints of German Shepherd Dogs.
  • Results of classification of hip dysplasia according to the Fédération Cynologique Internationale (FCI) and NAs were compared within dogs and among breeds.
  • The NA values accurately discriminated between hip joints of dogs without or with hip dysplasia, provided the values were also expressed as percentile rank based on the cumulative frequency distribution of NAs within the breed, and had good power to discriminate among various FCI classifications of hip joints.
  • Mean NA for each dog breed as calculated by use of the lower of 2 NAs for each dog was highly variable and was moderately correlated with the existence of hip dysplasia (r = 0.5).
  • [MeSH-major] Hip / radiography. Hip Dysplasia, Canine / classification. Hip Dysplasia, Canine / radiography

  • SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231956.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Switzer-Taylor V, Schlup M, Lübcke R, Livingstone V, Schultz M: Barrett's esophagus: a retrospective analysis of 13 years surveillance. J Gastroenterol Hepatol; 2008 Sep;23(9):1362-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, Barrett's mucosa was seen in 54%, low-grade dysplasia in 18%, ulcerations in 9%, high-grade dysplasia in 2%.
  • All patients who developed cancer were male and all but one patient had dysplasia or ulcerations on index endoscopy.
  • To stratify surveillance for Barrett's esophagus, programs could focus on male patients with dysplasia or ulcerations on index endoscopy.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol Hepatol. 2008 Sep;23(9):1311-2 [18853989.001]
  • (PMID = 18205769.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


41. Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM, Yavuzsen T, Yuksel E, Undar B: The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. Leuk Lymphoma; 2007 Jul;48(7):1372-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In WHO classification, significant differences were observed in both OS and leukaemia free survival (LFS) between patients with RA/RARS and refractory cytopenia with multi-lineage dysplasia/refractory cytopenia with multi-lineage dysplasia and ringed sideroblasts (RCMD/RS-RCMD) (p = 0.0001).


42. Nieminen P, Kotaniemi L, Hakama M, Tarkkanen J, Martikainen J, Toivonen T, Ikkala J, Luostarinen T, Anttila A: A randomised public-health trial on automation-assisted screening for cervical cancer in Finland: performance with 470,000 invitations. Int J Cancer; 2005 Jun 10;115(2):307-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 1,291 cases of histologically confirmed dysplasia or carcinoma (0.4% of the screened), one-third of which were severe dysplasia or a more severe finding (CIN3+).
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. Mass Screening. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis


43. Yap AK, Klineberg I: Dental implants in patients with ectodermal dysplasia and tooth agenesis: a critical review of the literature. Int J Prosthodont; 2009 May-Jun;22(3):268-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dental implants in patients with ectodermal dysplasia and tooth agenesis: a critical review of the literature.
  • PURPOSE: The aims of this article are to critique the available literature on dental implants in patients with ectodermal dysplasia (ED) syndrome and tooth agenesis, review the outcomes of implant therapy in these patients, and provide recommendations on the timing of implant placement for these patients.
  • Implants placed in adolescent ED patients do not have a significant effect on craniofacial growth, while implants placed in ED patients younger than 18 years have a higher risk of failure.
  • [MeSH-major] Anodontia / therapy. Dental Implants. Ectodermal Dysplasia / complications

  • Genetic Alliance. consumer health - Ectodermal Dysplasia.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548409.001).
  • [ISSN] 0893-2174
  • [Journal-full-title] The International journal of prosthodontics
  • [ISO-abbreviation] Int J Prosthodont
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dental Implants
  • [Number-of-references] 26
  •  go-up   go-down


44. Heinrich H, Bauerfeind P: Endoscopic mucosal resection for staging and therapy of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:85-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minamally invasive endoscopic resection techniques allow definitive histological staging for dysplasia and early cancer and in many cases curative treatment.
  • In Barrett's esophagus with High Grade Dysplasia (HGD) or early mucosal cancer, endoscopic mucosal resection (EMR) should be considered both as diagnostic and therapeutic first line procedure, with the possibility to repeat the procedure in case of residual Barrett's dysplasia or mucosal cancer.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676873.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


45. Bamford NS, White KK, Robinett SA, Otto RK, Gospe SM Jr: Neuromuscular hip dysplasia in Charcot-Marie-Tooth disease type 1A. Dev Med Child Neurol; 2009 May;51(5):408-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuromuscular hip dysplasia in Charcot-Marie-Tooth disease type 1A.
  • Here, we report on four children (aged 10-17y) who presented with neuromuscular hip dysplasia and other orthopedic abnormalities but were only later diagnosed with CMT 1A.
  • Hip dysplasia may be the initial clinical sign in CMT, so children with late-manifesting hip disease (i.e. age >8y) should be examined for signs of peripheral neuropathy, particularly when presenting with a 'waddling' or broad-based gait.


46. Riminucci M, Robey PG, Bianco P: The pathology of fibrous dysplasia and the McCune-Albright syndrome. Pediatr Endocrinol Rev; 2007 Aug;4 Suppl 4:401-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathology of fibrous dysplasia and the McCune-Albright syndrome.
  • Fibrous dysplasia (FD) is the most serious and least understood clinical expression in patients with activating mutations of the GNAS gene.
  • Furthermore, the recognition of FD as a disease of excess, abnormal and imperfect bone formation has helped to explain relevant mechanisms of its clinical morbidity, based on which potential specific therapeutic approaches may be developed in the near future.
  • [MeSH-major] Calcification, Physiologic. Fibrous Dysplasia of Bone / pathology. Fibrous Dysplasia, Polyostotic / pathology

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • Genetic Alliance. consumer health - McCune Albright syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982387.001).
  • [ISSN] 1565-4753
  • [Journal-full-title] Pediatric endocrinology reviews : PER
  • [ISO-abbreviation] Pediatr Endocrinol Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Israel
  • [Number-of-references] 69
  •  go-up   go-down


47. Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R: MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology; 2005;68(4-6):462-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Increased MEMD/ALCAM expression was observed in 42/65 (65%) ESCCs (p = 0.000, odds ratio, OR = 3.665) and in 17/25 (68%) dysplasias (p = 0.000, OR = 4.248) compared to paired distant histologically normal esophageal tissues.
  • Increased MEMD mRNAlevels were observed in ESCCs and dysplasias showing overexpression of MEMD/ALCAM protein.
  • Interestingly, increased membranous MEMD/ALCAM expression was observed in dysplasias in comparison with ESCCs (p = 0.002, OR = 3.177).
  • CONCLUSION: To our knowledge, this is the first report showing MEMD expression at pre-malignant stage (dysplasia), suggesting that MEMD/ALCAM expression is an early event in the development of esophageal cancer.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024937.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Activated-Leukocyte Cell Adhesion Molecule; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


48. Ramsebner R, Ludwig M, Parzefall T, Lucas T, Baumgartner WD, Bodamer O, Cengiz FB, Schoefer C, Tekin M, Frei K: A FGF3 mutation associated with differential inner ear malformation, microtia, and microdontia. Laryngoscope; 2010 Feb;120(2):359-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Auditory investigations, computer tomography, and genetic sequencing of the fibroblast growth factor 3 (FGF3) gene were performed on a Somali family presenting with autosomal recessive, hearing impairment, microdontia, and outer ear morphologies ranging from normal auricle development to microtia assessed as type 1 Weerda dysplasia in affected individuals.
  • CONCLUSIONS: These findings describe, for the first time, variable inner ear malformations and outer ear dysplasia in the presence of constant microdontia, associated with homozygous inheritance of the p.R95W mutation in FGF3, mirroring phenotypes observed in mouse models ablating FGF3/FGFR2 signaling.
  • [MeSH-major] Abnormalities, Multiple / genetics. Ear, External / abnormalities. Ear, Inner / abnormalities. Fibroblast Growth Factor 3 / genetics. Mutation, Missense. Tooth Abnormalities / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950373.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibroblast Growth Factor 3
  •  go-up   go-down


49. Righini CA, Darouassi Y, Boubagra K, Schmerber S, Reyt E: [Sphenoid sinus mucocele of unusual aetiology and location]. Rev Laryngol Otol Rhinol (Bord); 2006;127(3):165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imagery also revealed fibrous dysplasia of the anterior skull base which probably induced the mucocele formation.
  • The association of fibrous dysplasia and an anterior clinoidal mucocele is exceptional.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007190.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 24
  •  go-up   go-down


50. Vigneswaran N, Beckers S, Waigel S, Mensah J, Wu J, Mo J, Fleisher KE, Bouquot J, Sacks PG, Zacharias W: Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp Mol Pathol; 2006 Apr;80(2):147-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EMMPRIN was detected as high and low glycosylated forms in the OPM and OSCC cellular extracts and was released in the media by OSCC cells but not by OPM cells.
  • EMMPRIN expression is increased in dysplastic leukoplakias spreading to more superficial layers, and its expression levels correlated significantly with the degree of dysplasia.

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310185.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE13150; United States / NIDCR NIH HHS / DE / DE14395
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


51. Yamaguchi K, Nakamura M, Shirahane K, Kawamoto M, Konomi H, Ohta M, Tanaka M: Pancreatic juice cytology in IPMN of the pancreas. Pancreatology; 2005;5(4-5):416-21; discussion 421
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas is a disease ranging from adenoma to borderline (with moderate dysplasia) and further to carcinoma (noninvasive and invasive) and surgical strategy is different by the grades of dysplasia.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15985766.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


52. Morales Martínez A, Calvo Medina R, Chaffanel Peláez M, Bueno Fernández A, Míguelez Lago C, Acedo del Olmo Edel C: [Embryology and genetics of primary vesicoureteral reflux and associated renal dysplasia]. Arch Esp Urol; 2008 Mar;61(2):99-111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Embryology and genetics of primary vesicoureteral reflux and associated renal dysplasia].
  • [Transliterated title] Embriología y genética del reflujo vesicoureteral primario y de la displasia renal asociada.

  • Genetic Alliance. consumer health - Renal dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18491724.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 74
  •  go-up   go-down


53. Owens C, Bradley L, Farrell M, O'Brien D, King MD, Ryan SP: Seizure-induced inflammation in focal cortical dysplasia resulting in imaging progression that simulates neoplasia. J Neuroimaging; 2010 Apr;20(2):208-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seizure-induced inflammation in focal cortical dysplasia resulting in imaging progression that simulates neoplasia.
  • A 5-year-old girl with previously well-controlled partial epilepsy secondary to focal cortical dysplasia (FCD) developed an increase in seizure frequency.

  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187476.001).
  • [ISSN] 1552-6569
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Lücke T, Ehrich JH, Das AM: Mitochondrial function in schimke-immunoosseous dysplasia. Metab Brain Dis; 2005 Sep;20(3):237-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial function in schimke-immunoosseous dysplasia.
  • Schimke-immunoosseous dysplasia (SIOD) is a multisystemic disorder caused by a mutation of a putative chromatin remodelling protein.
  • Spondyloepiphyseal dysplasia with disproportionate growth deficiency, nephrotic syndrome with focal and segmental glomerulosclerosis, defective cellular immunity, and transient ischemic attacks are major clinical features in the severe form of SIOD.
  • [MeSH-major] Arteriosclerosis / metabolism. Growth Disorders / metabolism. Immune System Diseases / metabolism. Mitochondria / metabolism. Nephrotic Syndrome / metabolism. Osteochondrodysplasias / metabolism


55. Tandri H, Macedo R, Calkins H, Marcus F, Cannom D, Scheinman M, Daubert J, Estes M 3rd, Wilber D, Talajic M, Duff H, Krahn A, Sweeney M, Garan H, Bluemke DA, Multidisciplinary Study of Right Ventricular Dysplasia Investigators: Role of magnetic resonance imaging in arrhythmogenic right ventricular dysplasia: insights from the North American arrhythmogenic right ventricular dysplasia (ARVD/C) study. Am Heart J; 2008 Jan;155(1):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of magnetic resonance imaging in arrhythmogenic right ventricular dysplasia: insights from the North American arrhythmogenic right ventricular dysplasia (ARVD/C) study.
  • BACKGROUND: Prior reports describing magnetic resonance (MR) imaging abnormalities in arrhythmogenic right ventricular dysplasia (ARVD/C) were limited by nonuniform inclusion criteria.
  • The aim of our study was to define the prevalence, sensitivity, and specificity of quantitative MR imaging findings in the probands of multidisciplinary study of right ventricular dysplasia.
  • Qualitative RV function was abnormal in 26 probands (60%); however, quantitative RV ejection fraction was abnormal in 85% (24/28) of the probands.
  • CONCLUSIONS: Fat infiltration is seldom the only MR imaging abnormality and is less sensitive for ARVD/C diagnosis compared with RV regional dysfunction.
  • [MeSH-major] Adipose Tissue / pathology. Arrhythmogenic Right Ventricular Dysplasia / diagnosis. Magnetic Resonance Imaging / methods. Ventricular Dysfunction, Right / diagnosis


56. Bragg JW, Swindle L, Halpern AC, Marghoob AA: Agminated acquired melanocytic nevi of the common and dysplastic type. J Am Acad Dermatol; 2005 Jan;52(1):67-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agminated acquired melanocytic nevi of the common and dysplastic type.
  • The presence of an underlying dysplastic nevus syndrome phenotype in 4 of the 5 cases raises the possibility that agminated nevi arise as a consequence of postzygotic loss of heterozygosity and, thus, may represent a type 2 segmental manifestation of the atypical mole syndrome phenotype.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627083.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Krakow D, Vriens J, Camacho N, Luong P, Deixler H, Funari TL, Bacino CA, Irons MB, Holm IA, Sadler L, Okenfuss EB, Janssens A, Voets T, Rimoin DL, Lachman RS, Nilius B, Cohn DH: Mutations in the gene encoding the calcium-permeable ion channel TRPV4 produce spondylometaphyseal dysplasia, Kozlowski type and metatropic dysplasia. Am J Hum Genet; 2009 Mar;84(3):307-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the gene encoding the calcium-permeable ion channel TRPV4 produce spondylometaphyseal dysplasia, Kozlowski type and metatropic dysplasia.
  • The spondylometaphyseal dysplasias (SMDs) are a group of short-stature disorders distinguished by abnormalities in the vertebrae and the metaphyses of the tubular bones.
  • Metatropic dysplasia is another SMD that has been proposed to have both clinical and genetic heterogeneity.
  • Patients with the nonlethal form of metatropic dysplasia present with a progressive scoliosis, widespread metaphyseal involvement of the appendicular skeleton, and carpal ossification delay.
  • Because of some similar radiographic features between SMDK and metatropic dysplasia, TRPV4 was tested as a disease gene for nonlethal metatropic dysplasia.
  • The findings demonstrate that mutations in TRPV4 produce a phenotypic spectrum of skeletal dysplasias from the mild autosomal-dominant brachyolmia to SMDK to autosomal-dominant metatropic dysplasia, suggesting that these disorders should be grouped into a new bone dysplasia family.


58. Li W, Gao BD, Li LY, Xiao HM, Lu GX: [Mutation screening and prenatal diagnosis of hidrotic ectodermal dysplasia in a Chinese family]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec;23(6):618-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mutation screening and prenatal diagnosis of hidrotic ectodermal dysplasia in a Chinese family].
  • OBJECTIVE: To analyze the mutations in Cx30 gene in a Chinese family with hidrotic ectodermal dysplasia (HED) and to make prenatal diagnosis on the embryo which has been pregnant for 5 months.
  • [MeSH-major] Connexins / genetics. Ectodermal Dysplasia / genetics. Fetal Diseases / genetics. Mutation, Missense. Prenatal Diagnosis / methods

  • Genetic Alliance. consumer health - Ectodermal Dysplasia.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • MedlinePlus Health Information. consumer health - Prenatal Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160938.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Connexins; 0 / GJB6 protein, human
  •  go-up   go-down


59. Asthana N, Mandich D, Ligato S: Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus. Am J Surg Pathol; 2008 Oct;32(10):1581-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.
  • We describe a rare case of esophageal polypoid dysplasia with gastric phenotype and focal intramucosal carcinoma associated with Barrett's esophagus.
  • The histopathologic examination of this lesion revealed an exuberant polypoid gastric epithelium with areas of low-grade dysplasia, high-grade dysplasia, and focal intramucosal carcinoma.
  • A few residual foci of specialized intestinal metaplasia consistent with Barrett's esophagus without dysplasia were identified at the proximal and distal ends of the lesion.
  • In addition, in the dysplastic areas, there was high Ki-67 labeling index and no overexpression of p53 protein.


60. Kononov AV: [Interpretation of the notion "dysplasia/ intraepitelial neoplasia" in the international classification of tumors]. Arkh Patol; 2005 Nov-Dec;67(6):44-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interpretation of the notion "dysplasia/ intraepitelial neoplasia" in the international classification of tumors].
  • Principal definitions are considered, the content of terms "dysplastic" and "neoplasia" is analysed.
  • The attempt to systematize the description of morphological picture of neoplasia (adenoma/dysplasia) of low and high degree and difference of uncertain neoplastic (dysplasia) from true neoplastic changes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405022.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 34
  •  go-up   go-down


61. Bilchick KC, Judge DP, Calkins H, Marine JE: Use of a coronary sinus lead and biventricular ICD to correct a sensing abnormality in a patient with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol; 2006 Mar;17(3):317-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a coronary sinus lead and biventricular ICD to correct a sensing abnormality in a patient with arrhythmogenic right ventricular dysplasia/cardiomyopathy.
  • Implantable cardioverter defibrillators (ICDs) are frequently offered to patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C).
  • [MeSH-major] Arrhythmogenic Right Ventricular Dysplasia / therapy. Cardiomyopathies / therapy. Defibrillators, Implantable


62. Engesaeter LB, Furnes O, Havelin LI: Developmental dysplasia of the hip--good results of later total hip arthroplasty: 7135 primary total hip arthroplasties after developmental dysplasia of the hip compared with 59774 total hip arthroplasties in idiopathic coxarthrosis followed for 0 to 15 years in the Norwegian Arthroplasty Register. J Arthroplasty; 2008 Feb;23(2):235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developmental dysplasia of the hip--good results of later total hip arthroplasty: 7135 primary total hip arthroplasties after developmental dysplasia of the hip compared with 59774 total hip arthroplasties in idiopathic coxarthrosis followed for 0 to 15 years in the Norwegian Arthroplasty Register.
  • The purpose of the present article was to compare the results of primary total hip arthroplasty (THA) done because of developmental dysplasia of the hip (DDH) with the results of THA done because of idiopathic coxarthrosis (osteoarthritis) using data from the nationwide Norwegian Arthroplasty Register (NAR).

  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18280418.001).
  • [ISSN] 0883-5403
  • [Journal-full-title] The Journal of arthroplasty
  • [ISO-abbreviation] J Arthroplasty
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Amstutz HC, Le Duff MJ, Harvey N, Hoberg M: Improved survivorship of hybrid metal-on-metal hip resurfacing with second-generation techniques for Crowe-I and II developmental dysplasia of the hip. J Bone Joint Surg Am; 2008 Aug;90 Suppl 3:12-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survivorship of hybrid metal-on-metal hip resurfacing with second-generation techniques for Crowe-I and II developmental dysplasia of the hip.
  • BACKGROUND: The purpose of this study was to determine the influence of improved femoral fixation techniques on the survivorship of metal-on-metal total hip resurfacing prostheses in patients with developmental dysplasia of the hip and to report the long-term results of our patients managed earlier with first-generation fixation techniques.
  • METHODS: One hundred and three hips (ninety patients) were resurfaced for osteoarthritis secondary to developmental dysplasia.
  • Range of motion was greater for the patients with dysplasia than for the patients with other etiologies.
  • CONCLUSIONS: The current improvements in the short-term to midterm results after resurfacing in patients with developmental dysplasia of the hip in whom more current techniques were used are encouraging and allow for greater expectations regarding the elimination of short-term failures and improved long-term durability of resurfacing in this population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676931.001).
  • [ISSN] 1535-1386
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromium Alloys
  •  go-up   go-down


64. Yu CH, Chen HM, Hung HY, Cheng SJ, Tsai T, Chiang CP: Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion. Oral Oncol; 2008 Jun;44(6):595-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion.
  • OVH lesions with an clinical appearance of a mass, with the greatest diameter <1.5 cm, with the pink color, with epithelial dysplasia, or with the surface keratin layer < or =40 microm needed significantly less mean treatment numbers of PDT to achieve a CR than OVH lesions with an outer appearance of a plaque or a combination type of peripheral plaque and central mass (p=0.000), with the greatest diameter > or =1.5 cm (p=0.011), with the white color (p=0.000), without epithelial dysplasia (p=0.043), or with the surface keratin layer > 40 microm(p=0.003), respectively.
  • The PDT treatment outcome for OVH depends on the outer appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203648.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


65. Schaakxs D, Bahm J, Sellhaus B, Weis J: Clinical and neuropathological study about the neurotization of the suprascapular nerve in obstetric brachial plexus lesions. J Brachial Plex Peripher Nerve Inj; 2009;4:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also looked at the influence of the restoration of the muscular balance between the internal and the external rotators on the development of a gleno-humeral joint dysplasia.
  • The neurotization operation has a positive influence on the glenohumeral joint: 7 patients with clinical signs of dysplasia before the reconstructive operation did not show any sign of dysplasia in the postoperative follow-up.
  • CONCLUSION: The neurotization procedure helps to recover the active external rotation in the shoulder joint and has a good prevention influence on the dysplasia in our sample.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hand Surg Am. 2007 Sep;32(7):989-98 [17826551.001]
  • [Cites] J Pediatr Orthop B. 2007 Jul;16(4):243-51 [17527100.001]
  • [Cites] J Brachial Plex Peripher Nerve Inj. 2007;2:1 [17214900.001]
  • [Cites] Handchir Mikrochir Plast Chir. 2004 Feb;36(1):37-46 [15083389.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):530-7; discussion 530-7 [16145533.001]
  • [Cites] Plast Reconstr Surg. 2005 Jan;115(1):240-4 [15622257.001]
  • [Cites] J Pediatr Orthop. 2004 Mar-Apr;24(2):189-93 [15076606.001]
  • [Cites] Neurosurgery. 2006 Oct;59(4):858-67; discussion 867-9 [17038950.001]
  • (PMID = 19744351.001).
  • [ISSN] 1749-7221
  • [Journal-full-title] Journal of brachial plexus and peripheral nerve injury
  • [ISO-abbreviation] J Brachial Plex Peripher Nerve Inj
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2753616
  •  go-up   go-down


66. Hritz I, Gyorffy H, Molnar B, Lakatos G, Sipos F, Pregun I, Juhasz M, Pronai L, Schaff Z, Tulassay Z, Herszenyi L: Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment. Pathol Oncol Res; 2009 Jun;15(2):183-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PCNA and p53 expressions were analyzed in biopsy samples by immunohistochemistry including patients with reflux esophagitis, BE, BE with concomitant esophagitis, Barrett's dysplasia, esophageal adenocarcinoma and a control group without any histological changes.
  • While cell proliferation was significantly lower in the control group compared with all other groups, there was no increase in p53 expression of esophageal tissues that were negative for dysplasia.
  • Dysplastic BE tissues revealed significantly higher cell proliferation and p53 expression levels compared to BE, reflux esophagitis or BE with concomitant esophagitis.
  • Both, cell proliferation and p53 expression were significantly higher in adenocarcinoma compared to BE or Barrett's dysplasia.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Mod Pathol. 2001 May;14(5):397-403 [11353048.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12):707-13 [16314343.001]
  • [Cites] Dig Dis Sci. 1997 Dec;42(12):2453-62 [9440619.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1637-42 [8253340.001]
  • [Cites] Gastroenterology. 1988 Jan;94(1):81-90 [3335302.001]
  • [Cites] Histopathology. 2000 Aug;37(2):99-107 [10931231.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1169-74 [8118801.001]
  • [Cites] Oncol Rep. 1999 Jul-Aug;6(4):877-82 [10373674.001]
  • [Cites] Dis Esophagus. 2002;15(1):10-5 [12060037.001]
  • [Cites] Surg Oncol. 1995 Jun;4(3):163-71 [7582189.001]
  • [Cites] Dig Dis Sci. 1998 Jul;43(7):1501-6 [9690386.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):585-93 [17406989.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1220-8 [1551529.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):1118-29 [17990321.001]
  • [Cites] N Engl J Med. 1986 Aug 7;315(6):362-71 [2874485.001]
  • [Cites] Dig Dis Sci. 1997 Aug;42(8):1747-54 [9286244.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i6-12 [15711008.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1573 [15619221.001]
  • [Cites] World J Gastroenterol. 2007 Feb 7;13(5):676-82 [17278189.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1554-66 [15887151.001]
  • [Cites] Methods Mol Biol. 2003;234:231-43 [12824536.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5572-9 [15328199.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7937-41 [2253235.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):119-29 [8514029.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 1;23(5):587-93 [16480397.001]
  • [Cites] Am J Gastroenterol. 1996 Feb;91(2):271-6 [8607492.001]
  • [Cites] World J Gastroenterol. 2005 Aug 14;11(30):4721-6 [16094717.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3383-7 [11151865.001]
  • [Cites] Int J Immunopathol Pharmacol. 2005 Jan-Mar;18(1):75-84 [15698513.001]
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):226-31 [15729230.001]
  • [Cites] Nature. 1987 Apr 2-8;326(6112):517-20 [2882424.001]
  • [Cites] Dis Esophagus. 2004;17(1):67-70 [15209744.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Feb;111(2):323-31; discussion 331-3 [8583805.001]
  • [Cites] Cancer. 1994 Dec 15;74(12):3089-96 [7982172.001]
  • [Cites] J Clin Pathol. 1993 Apr;46(4):330-3 [8496390.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jan;130(1):37-44 [14569466.001]
  • [Cites] Dig Dis Sci. 1997 Apr;42(4):697-701 [9125634.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Mar;18(3):277-82 [16462541.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):38-47 [18076737.001]
  • [Cites] Ann Surg. 1997 Jan;225(1):17-30 [8998117.001]
  • [Cites] Scand J Gastroenterol. 2000 Dec;35(12):1238-44 [11199360.001]
  • (PMID = 18752044.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


67. Amano Y, Kushiyama Y, Ishihara S, Yuki T, Miyaoka Y, Yoshino N, Ishimura N, Fujishiro H, Adachi K, Maruyama R, Rumi MA, Kinoshita Y: Crystal violet chromoendoscopy with mucosal pit pattern diagnosis is useful for surveillance of short-segment Barrett's esophagus. Am J Gastroenterol; 2005 Jan;100(1):21-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: This study was undertaken to evaluate the abilities of crystal violet and methylene blue chromoendoscopy to detect potentially dysplastic Barrett's epithelium in cases with short-segment columnar-appearing epithelium of the esophago-gastric junction.
  • The value of pit pattern diagnosis was also evaluated as a possible way to detect dysplastic Barrett's epithelium.
  • Crystal violet clearly stained both dysplastic and nondysplastic Barrett's epithelia and made the surface pit pattern easy to observe without using magnifying endoscopy.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • Hazardous Substances Data Bank. Gentian Violet .
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654776.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; J4Z741D6O5 / Gentian Violet; T42P99266K / Methylene Blue
  •  go-up   go-down


68. van de Vyver A, Delport E, Visser A: Decreased CD10 Expression in the Bone Marrow Neutrophils of HIV Positive Patients. Mediterr J Hematol Infect Dis; 2010;2(3):e2010032
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear distinction between primary myelodysplastic syndrome (MDS) and secondary dysplasia may not always be possible.
  • Much focus has been placed on establishing FCM guidelines aiding in the diagnosis of MDS, and to distinguish this condition from secondary dysplastic changes.
  • Bone marrow aspirate samples were evaluated in terms of morphological abnormality as well as CD10 expression on the granulocytic population.
  • DISCUSSION: Disease conditions causing secondary dysplasia, especially HIV-1 infection, is associated with a marked reduction in CD10 expression on the granulocyte population independent from the presence of myelodysplastic features.
  • This marker is therefore of doubtful significance as a diagnostic tool in distinguishing between primary and secondary dysplasia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Aug 15;98(4):979-87 [11493442.001]
  • [Cites] Intern Med. 2001 Aug;40(8):795-801 [11518128.001]
  • [Cites] J Infect Dis. 2002 May 15;185 Suppl 2:S105-9 [12001030.001]
  • [Cites] Blood. 2002 Dec 1;100(12):3887-96 [12393641.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):187-200 [12542475.001]
  • [Cites] J Infect. 2007 Apr;54(4):362-6 [16875738.001]
  • [Cites] Leuk Res. 2008 Jan;32(1):5-17 [17576013.001]
  • [Cites] Haematologica. 2009 Aug;94(8):1124-34 [19546437.001]
  • [Cites] Haematologica. 2009 Aug;94(8):1066-74 [19546439.001]
  • [Cites] J Virol. 1991 Apr;65(4):1765-9 [2002542.001]
  • [Cites] J Clin Pathol. 1988 Jul;41(7):711-5 [3045157.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Leukemia. 1997 Apr;11 Suppl 3:123-7 [9209318.001]
  • [Cites] J Assoc Physicians India. 2005 Aug;53:705-10 [16398081.001]
  • [Cites] Ann Hematol. 1992 Jan;64(1):43-5 [1739758.001]
  • [Cites] Blood. 1989 Feb 15;73(3):625-35 [2465037.001]
  • [Cites] Eur J Haematol. 1989 Apr;42(4):339-43 [2721658.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Dec;82(24):8737-41 [3909153.001]
  • [Cites] Am J Clin Pathol. 1985 Aug;84(2):144-52 [4025220.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):409-12 [7803293.001]
  • [Cites] Blood. 1993 Aug 15;82(4):1052-70 [8102558.001]
  • [Cites] Virology. 1996 Jan 1;215(1):51-60 [8553586.001]
  • [Cites] Blood. 1996 Feb 1;87(3):919-25 [8562963.001]
  • [Cites] Acta Haematol. 1996;95(3-4):204-12 [8677744.001]
  • [Cites] Anal Cell Pathol. 1996 Aug;11(3):141-57 [8888951.001]
  • [Cites] Am J Clin Pathol. 1997 Mar;107(3):261-4 [9052374.001]
  • [Cites] Med Clin North Am. 1997 Mar;81(2):449-70 [9093237.001]
  • (PMID = 21776338.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3134218
  •  go-up   go-down


69. Thompson S, Shakespeare T, Wright MJ: Medical and social aspects of the life course for adults with a skeletal dysplasia: a review of current knowledge. Disabil Rehabil; 2008;30(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical and social aspects of the life course for adults with a skeletal dysplasia: a review of current knowledge.
  • PURPOSE: The paper examines the general literature and available research evidence on medical, health and social aspects of life for adults with skeletal dysplasia conditions causing profound short stature.

  • MedlinePlus Health Information. consumer health - Dwarfism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852222.001).
  • [ISSN] 0963-8288
  • [Journal-full-title] Disability and rehabilitation
  • [ISO-abbreviation] Disabil Rehabil
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 50
  •  go-up   go-down


70. Epari K, Cade R: Oesophagectomy for tumours and dysplasia of the oesophagus and gastro-oesophageal junction. ANZ J Surg; 2009 Apr;79(4):251-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oesophagectomy for tumours and dysplasia of the oesophagus and gastro-oesophageal junction.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432710.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


71. Zhang H, Quan C, Gao M, Xiao FL, Lu WS, Shen YJ, Zhou FS, Yang S, Zhang XJ: [Genetical diagnosis in a family with X-linked hypohidrotic ectodermal dysplasia]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Apr;29(2):201-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genetical diagnosis in a family with X-linked hypohidrotic ectodermal dysplasia].
  • OBJECTIVE: To identify the mutations of ED1 gene in a family with X-linked hypohidrotic ectodermal dysplasia METHODS: Eight coding exons of ED1 gene of two patients with clinically confirmed X-linked hypohidrotic ectodermal dysplasia, their parents, and 100 unrelated population-matched control were amplified by polymerase chain reaction.
  • RESULTS: Two patients with X-linked hypohidrotic ectodermal dysplasia in this pedigree showed a point mutation at nucleotide 1 045 ( A > G) .
  • CONCLUSION: The c. 1 045A > G mutation of ED1 gene may be the pathologic cause of this Chinese family with X-linked hypohidrotic ectodermal dysplasia.
  • [MeSH-major] Ectodermal Dysplasia 1, Anhidrotic / genetics. Ectodysplasins / genetics


72. Hart ES, Albright MB, Rebello GN, Grottkau BE: Developmental dysplasia of the hip: nursing implications and anticipatory guidance for parents. Orthop Nurs; 2006 Mar-Apr;25(2):100-9; quiz 110-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developmental dysplasia of the hip: nursing implications and anticipatory guidance for parents.
  • Developmental dysplasia of the hip (DDH) is a comprehensive term used to describe an abnormal relationship between the femoral head and the acetabulum.
  • Developmental dysplasia of the hip includes a very wide spectrum of abnormality from a frank dislocation (very unstable) to a stable hip with a slightly shallow acetabulum.
  • Despite the recent increased awareness of DDH and the importance of thorough screening programs, hip dysplasia continues to be a frequently missed diagnosis in pediatrics.
  • [MeSH-minor] Algorithms. Casts, Surgical. Counseling / organization & administration. Diagnostic Errors. Hip Joint / anatomy & histology. Hip Joint / growth & development. Humans. Incidence. Infant. Infant, Newborn. Neonatal Screening. Orthopedic Nursing / methods. Patient Care Planning. Pediatric Nursing / methods. Physical Examination. Professional-Family Relations. Prognosis. Referral and Consultation. Risk Factors. Social Support. Splints

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16572026.001).
  • [ISSN] 0744-6020
  • [Journal-full-title] Orthopedic nursing
  • [ISO-abbreviation] Orthop Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


73. Hong L, Li S, Liu L, Shi Y, Wu K, Fan D: The value of MG7-Ag and COX-2 for predicting malignancy in gastric precancerous lesions. Cell Biol Int; 2010 Sep;34(9):873-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical analysis was used to examine the expression of MG7-Ag and COX-2 in 396 cases of patients with gastric precancerous lesions, including 66 cases of atrophic gastritis, 106 cases of intestinal metaplasia, 174 cases of low-moderate-grade dysplasia and 50 cases of high-grade dysplasia.
  • The positive rates of MG7-Ag and COX-2 were increased gradually from atrophic gastritis (21.2%, 28.8%), intestinal metaplasia (36.8%, 44.3%), low-moderate-grade dysplasia (51.4%, 58.6%) to high-grade dysplasia (72%, 80%).


74. Rubin DT, Parekh N: Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. Curr Treat Options Gastroenterol; 2006 Jun;9(3):211-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Precancerous dysplasia has been associated with concurrent or future CRC in UC and, although less studied, in CD, and is therefore considered a marker of cancer risk in inflammatory bowel disease (IBD).
  • Risk factors for dysplasia and CRC in IBD include longer duration of disease, greater extent of disease, younger age at diagnosis, diagnosis with primary sclerosing cholangitis (PSC), family history of CRC, and possibly backwash ileitis and degree of inflammation of the bowel over time.
  • Prevention of cancer in IBD has been focused on secondary measures of identifying dysplasia in flat mucosa or protruding lesions during surveillance colonoscopy with random biopsies and, when confirmed, performing proctocolectomy.
  • Studies of primary prevention of dysplasia and CRC using chemopreventive agents have suggested a possible benefit with a number of agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2004 Feb;126(2):451-9 [14762782.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Nov;13(11):1397-402 [10571594.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):934-44 [7926483.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):29-32 [8978339.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):57-62 [9428784.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):117-20 [7912678.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):889-93 [12671884.001]
  • [Cites] Gastroenterology. 1992 Nov;103(5):1611-20 [1426881.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):841-7 [11231938.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2184-92 [15917383.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Oct;3(10):1015-21 [16234048.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1643-9 [10364038.001]
  • [Cites] Am J Gastroenterol. 2004 Jul;99(7):1371-85 [15233681.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Mar;26(1):129-39 [9119437.001]
  • [Cites] Gut. 2005 Nov;54(11):1573-8 [15994215.001]
  • [Cites] Inflamm Bowel Dis. 2002 Sep;8(5):356-61 [12479651.001]
  • [Cites] Lancet. 1994 Jan 8;343(8889):71-4 [7903776.001]
  • [Cites] Gastroenterology. 1989 Aug;97(2):255-9 [2568304.001]
  • [Cites] Gut. 2004 Sep;53 Suppl 5:V1-16 [15306569.001]
  • [Cites] Gastroenterology. 2004 May;126(6):1634-48 [15168373.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):379-86 [11950911.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:15-21 [12950416.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1345-53 [15929768.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1079-83 [9797361.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1288-94; discussion 1488-91 [10579969.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1311-9 [14598247.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2784-8 [14687833.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1996 Dec;8(12):1179-83 [8980937.001]
  • [Cites] Gastroenterology. 1993 Aug;105(2):418-24 [8335197.001]
  • [Cites] Hum Pathol. 1983 Nov;14 (11):931-68 [6629368.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1295-300 [10579970.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):79-83 [12556963.001]
  • (PMID = 16901385.001).
  • [ISSN] 1092-8472
  • [Journal-full-title] Current treatment options in gastroenterology
  • [ISO-abbreviation] Curr Treat Options Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Sabo E, Beck AH, Montgomery EA, Bhattacharya B, Meitner P, Wang JY, Resnick MB: Computerized morphometry as an aid in determining the grade of dysplasia and progression to adenocarcinoma in Barrett's esophagus. Lab Invest; 2006 Dec;86(12):1261-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized morphometry as an aid in determining the grade of dysplasia and progression to adenocarcinoma in Barrett's esophagus.
  • The aims of this study were to use computerized morphometry in order to differentiate between the degree of dysplasia and to predict progression to invasive adenocarcinoma in Barrett's esophagus (BE).
  • The study group included 36 biopsies negative for dysplasia (ND), none of which progressed to carcinoma; 16 indefinite for dysplasia (IND) and 21 low-grade dysplasia (LGD), of which three progressed in each group and 24 high-grade dysplasia (HGD), of which 15 progressed to invasive carcinoma.
  • Low-grade dysplasia was best differentiated from the ND group by nuclear pseudostratification (P=0.036), pleomorphism (P<0.01), and chromatin texture (margination, P<0.01) and from the HGD group by nuclear area (P<0.01), pleomorphism (P<0.01), chromatin texture (margination, P<0.01), symmetry (P<0.01), and orientation (P=0.027).
  • This study proposes that computerized morphometry is a valid tool for determining the grade of dysplasia in BE.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075582.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR17695
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


76. Leunig M, Parvizi J, Ganz R: Nonarthroplasty surgical treatment of hip osteoarthritis. Instr Course Lect; 2006;55:159-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two conditions that give rise to osteoarthritis of the hip are dysplasia and nondysplasia.
  • Dysplasia, commonly associated with anterolateral acetabular deficiency, may lead to osteoarthritis in 40% of patients in the United States with this condition.
  • There is emerging evidence that subtle morphologic abnormalities around the hip, resulting in femoroacetabular impingement, may often be a contributing factor to osteoarthritis in young patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16958448.001).
  • [ISSN] 0065-6895
  • [Journal-full-title] Instructional course lectures
  • [ISO-abbreviation] Instr Course Lect
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


77. Zhao H, Davydova L, Mandich D, Cartun RW, Ligato S: S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct. Am J Clin Pathol; 2007 Mar;127(3):374-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct.
  • We evaluated the expression of S100A4 protein and mesothelin in dysplasia and carcinoma of the extrahepatic bile duct (EBD) and their potential use as adjuncts for differentiating carcinomatous and significant high-grade dysplastic epithelium from reactive or inflammatory glandular atypia of the EBD.
  • We used immunohistochemical analysis on formalin-fixed tissue sections from 10 cases of carcinoma, 6 cases of high-grade dysphasia (HGD), 4 cases of low-grade dysplasia (LGD), and 10 cases of benign or reactive or inflammatory epithelium from the EBD.
  • S100A4 protein alone or combined with mesothelin can be used as an adjunct in differentiating carcinomatous and significant high-grade dysplastic epithelium from LGD and reactive or inflammatory glandular atypia of the EBD.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276942.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / S100 Proteins; 0 / mesothelin; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


78. Kayalvizhi G, Neeraja R: Christ-Siemens-Touraine Syndrome with Self-mutilation Habit: An Unusual Presentation. Int J Clin Pediatr Dent; 2009 Jan;2(1):52-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ectodermal dysplasia exhibits a classic triad of hypohidrosis, hypotrichosis, and hypodontia.
  • In most of the instances dentists are the first to recognize patient with ectodermal dysplasia as they report primarily with a complaint of missing teeth.
  • The most common type is hypohidrotic ectodermal dysplasia (Christ-Siemens-Touraine syndrome).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25206102.001).
  • [ISSN] 0974-7052
  • [Journal-full-title] International journal of clinical pediatric dentistry
  • [ISO-abbreviation] Int J Clin Pediatr Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4086548
  • [Keywords] NOTNLM ; Christ-Siemens-Touraine syndrome / Ectodermal dysplasia / Hypodontia / Hypohidrotic / Prosthetic treatment. / Self- mutilation
  •  go-up   go-down


79. Kim JH, Kim JH, Han JH, Yoo BM, Kim MW, Kim WH: Is endoscopic papillectomy safe for ampullary adenomas with high-grade dysplasia? Ann Surg Oncol; 2009 Sep;16(9):2547-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is endoscopic papillectomy safe for ampullary adenomas with high-grade dysplasia?
  • Coexistence of cancer in patients with pre-high-grade dysplasia (HGD) was 50.0% (5/10), whereas it was 15.7% in pre-low-grade dysplasia (LGD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19568817.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Boer K, Troost D, Spliet WG, van Rijen PC, Gorter JA, Aronica E: Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB. Acta Neuropathol; 2008 Jun;115(6):683-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB.
  • Members of the vascular endothelial growth factor (VEGF) family are key signaling proteins in the induction and regulation of angiogenesis, both during development and in pathological conditions.
  • In the present study, we immunocytochemically investigated the expression and cellular distribution of VEGFA, VEGFB, and their associated receptors (VEGFR-1 and VEGFR-2) in focal cortical dysplasia (FCD) type IIB from patients with medically intractable epilepsy.
  • In all FCD specimens, VEGFA, VEGFB, and both VEGF receptors were highly expressed in dysplastic neurons.
  • The neuronal expression of both VEGFA and VEGFB, together with their specific receptors in FCD, suggests autocrine/paracrine effects on dysplastic neurons.
  • These autocrine/paracrine effects could play a role in the development of FCD, preventing the death of abnormal neuronal cells.
  • In addition, the expression of VEGFA and its receptors in glial cells within the dysplastic cortex indicates that VEGF-mediated signaling could contribute to astroglial activation and associated inflammatory reactions.
  • [MeSH-major] Malformations of Cortical Development / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor B / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):117-30 [10579917.001]
  • [Cites] Eur J Neurosci. 2000 Jul;12(7):2623-33 [10947836.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10242-7 [10963684.001]
  • [Cites] Neuroscience. 2000;100(4):713-7 [11036205.001]
  • [Cites] Brain Res. 2000 Nov 10;883(1):87-97 [11063991.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):59-65 [11191064.001]
  • [Cites] Neuro Oncol. 2000 Apr;2(2):80-6 [11303624.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):131-8 [11381259.001]
  • [Cites] Acta Haematol. 2001;106(4):148-56 [11815711.001]
  • [Cites] Neuroscience. 2002;110(4):589-604 [11934468.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):212-33 [11958376.001]
  • [Cites] Semin Cell Dev Biol. 2002 Feb;13(1):39-53 [11969370.001]
  • [Cites] J Histochem Cytochem. 2002 Jun;50(6):767-77 [12019293.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11946-50 [12181492.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Sep;61(9):778-88 [12230324.001]
  • [Cites] Brain. 2002 Nov;125(Pt 11):2549-57 [12390979.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Sep;57(9):874-82 [9737551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15809-14 [9861052.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):417-25 [10211994.001]
  • [Cites] Dev Dyn. 1999 May;215(1):12-25 [10340753.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jun;58(6):654-66 [10374756.001]
  • [Cites] Circulation. 1999 Aug 10;100(6):583-6 [10441093.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Oct;24(10):1146-52 [15529014.001]
  • [Cites] Epilepsia. 2004 Dec;45(12):1517-24 [15571509.001]
  • [Cites] J Neurosci Res. 2005 Jan 1-15;79(1-2):180-4 [15573409.001]
  • [Cites] Curr Vasc Pharmacol. 2005 Jan;3(1):11-39 [15638780.001]
  • [Cites] Expert Rev Neurother. 2004 Nov;4(6):973-84 [15853524.001]
  • [Cites] J Thromb Haemost. 2005 Aug;3(8):1835-42 [16102050.001]
  • [Cites] Neuroscience. 2005;134(4):1167-78 [16039796.001]
  • [Cites] J Neurosci. 2005 Sep 28;25(39):8889-97 [16192378.001]
  • [Cites] Pulm Pharmacol Ther. 2006;19(1):61-9 [16286239.001]
  • [Cites] Epilepsia. 2005 Nov;46(11):1724-43 [16302852.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):954-9 [16355213.001]
  • [Cites] Dev Biol. 2006 Jan 15;289(2):329-35 [16337622.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):26-36 [16410746.001]
  • [Cites] J Neuroimmunol. 2006 Apr;173(1-2):188-95 [16483671.001]
  • [Cites] Neuroreport. 2006 May 15;17(7):705-9 [16641673.001]
  • [Cites] Development. 2006 Jun;133(11):2201-10 [16672338.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2879-87 [16631753.001]
  • [Cites] FASEB J. 2006 Jun;20(8):1185-7 [16641198.001]
  • [Cites] Mini Rev Med Chem. 2006 Jun;6(6):667-9 [16787377.001]
  • [Cites] Neurobiol Dis. 2006 Oct;24(1):128-43 [16860990.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5574-84 [17015745.001]
  • [Cites] FEBS Lett. 2006 Oct 30;580(25):5869-74 [17027979.001]
  • [Cites] Scand J Immunol. 2006 Dec;64(6):609-22 [17083617.001]
  • [Cites] Mol Divers. 2006 Nov;10(4):515-27 [16972015.001]
  • [Cites] Brain. 2007 Feb;130(Pt 2):521-34 [17124188.001]
  • [Cites] J Neurotrauma. 2007 Mar;24(3):521-31 [17402857.001]
  • [Cites] Neurobiol Dis. 2007 Jun;26(3):497-511 [17412602.001]
  • [Cites] Acta Neuropathol. 2007 Jun;113(6):607-26 [17492293.001]
  • [Cites] Brain. 2007 Jul;130(Pt 7):1942-56 [17533168.001]
  • [Cites] Neuropathol Appl Neurobiol. 2007 Aug;33(4):455-70 [17617874.001]
  • [Cites] Neurobiol Dis. 2008 Jan;29(1):142-60 [17931873.001]
  • [Cites] Neuroscience. 2008 Jan 2;151(1):232-41 [18065154.001]
  • [Cites] J Neuroimmunol. 2002 Nov;132(1-2):93-8 [12417438.001]
  • [Cites] Epilepsia. 2003 Jun;44(6):785-95 [12790891.001]
  • [Cites] J Clin Invest. 2003 Jun;111(12):1843-51 [12813020.001]
  • [Cites] Brain. 2003 Aug;126(Pt 8):1755-66 [12805104.001]
  • [Cites] Circ Res. 2003 Jul 25;93(2):114-23 [12805240.001]
  • [Cites] J Neurosci. 2003 Nov 26;23(34):10841-51 [14645477.001]
  • [Cites] Neurology. 2004 Mar 23;62(6 Suppl 3):S2-8 [15037671.001]
  • [Cites] Exp Neurol. 2004 Jun;187(2):388-402 [15144865.001]
  • [Cites] Adv Exp Med Biol. 2004;548:57-68 [15250585.001]
  • [Cites] Med Sci Monit. 2004 Apr;10(4):RA89-98 [15039660.001]
  • [Cites] Nat Genet. 2004 Aug;36(8):827-35 [15258583.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Aug;30(4):351-9 [15305980.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] Neurosurgery. 1990 Jan;26(1):93-101 [2294484.001]
  • [Cites] Am J Physiol. 1993 Apr;264(4 Pt 1):C995-1002 [8476026.001]
  • [Cites] J Leukoc Biol. 1994 Mar;55(3):410-22 [7509844.001]
  • [Cites] Circ Res. 1995 Sep;77(3):638-43 [7641334.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2576-81 [8637916.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jan 13;230(2):413-8 [9016794.001]
  • [Cites] Acta Neuropathol. 1997 Feb;93(2):109-17 [9039457.001]
  • [Cites] Oncogene. 1997 May 22;14(20):2475-83 [9188862.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7086-91 [9618543.001]
  • [Cites] J Am Soc Nephrol. 1998 Jun;9(6):1032-44 [9621286.001]
  • [Cites] Biochim Biophys Acta. 1998 Jun 16;1398(2):157-63 [9689915.001]
  • (PMID = 18317782.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Glial Fibrillary Acidic Protein; 0 / MAP2 protein, human; 0 / Microtubule-Associated Proteins; 0 / Neurofilament Proteins; 0 / VEGFA protein, human; 0 / VEGFB protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor B; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2386160
  •  go-up   go-down


81. Gatenby PA, Ramus JR, Caygill CP, Shepherd NA, Watson A: Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol; 2008;43(5):524-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus.
  • OBJECTIVE: In the USA, detection of intestinal metaplasia is a requirement for enrollment in surveillance programmes for dysplasia or adenocarcinoma in columnar-lined oesophagus.
  • MATERIAL AND METHODS: Demonstration of intestinal metaplasia was analysed in 3568 biopsies of non-dysplastic columnar-lined oesophagus from 1751 patients from 7 centres in the UK.
  • Development of dysplasia and adenocarcinoma was analysed in 322 patients without intestinal metaplasia and compared with that in 612 patients with intestinal metaplasia.
  • There was no significant difference in the rate of development of dysplasia or adenocarcinoma between patients with or without intestinal metaplasia detection at index endoscopy.
  • The decision to offer surveillance should not be based upon the presence or absence of intestinal metaplasia at index endoscopy as the risk of dysplasia and adenocarcinoma is similar in both groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415743.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


82. Ulu MO, Tanriverdi T, Oz B, Biceroglu H, Isler C, Eraslan BS, Ozkara C, Ozyurt E, Uzan M: The expression of astroglial glutamate transporters in patients with focal cortical dysplasia: an immunohistochemical study. Acta Neurochir (Wien); 2010 May;152(5):845-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of astroglial glutamate transporters in patients with focal cortical dysplasia: an immunohistochemical study.
  • PURPOSE: An abnormal increase in the extracellular glutamate is thought to play a crucial role in the initiation, spread, and maintenance of seizure activity.In normal conditions, the majority of this excess glutamate is cleared via glial glutamate transporters (EAAT-1 and EAAT-2).
  • We aimed to examine the immunohistochemical expression of these transporters in the dysplastic tissues of patients with focal cortical dysplasia (FCD).
  • METHODS: The parafin-embedded dysplastic tissues of 33 patients who were operated on due to medically intractable epilepsy and histopathologically diagnosed with FCD between 2001 and 2006 were stained immunohistochemically with appropriate antibodies, and the distribution and intensity of immunoreactivity (IR) of EAAT-1 and EAAT-2 were examined.The findings were compared with the histologically normal tissues of five patients who underwent temporal lobectomy for epilepsy surgery and 10 fresh postmortem cases.
  • RESULTS: In the majority of the patients, the EAAT-1 and EAAT-2 IR were decreased, their astrocytic expression were lower, and the pattern of distribution were more diffused when compared to the control groups.Analyzing these findings according to the types of FCD revealed that as the severity of the dysplasia increased, the IR and astrocytic expression of both transporters are decreased and their distribution tend to be more "diffused."
  • CONCLUSION: The results of this study suggest a relationship between the decreased glutamate transporter expressions in dysplastic tissues which,in turn, may cause increased extracellular concentrations of glutamate and FCD pathophysiology.Further studies with larger patient populations,investigating the expression of glutamate transporters at mRNA and protein levels, are required to clarify their roles in the pathophysiology of FCD.

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859653.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Excitatory Amino Acid Transporter 1; 0 / Excitatory Amino Acid Transporter 2; 0 / Vesicular Glutamate Transport Proteins; 3KX376GY7L / Glutamic Acid
  •  go-up   go-down


83. Hau RC, Newman JH: Knee replacement for osteoarthritis secondary to chronic patellar dislocation and trochlear dysplasia. Knee; 2008 Dec;15(6):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knee replacement for osteoarthritis secondary to chronic patellar dislocation and trochlear dysplasia.

  • Genetic Alliance. consumer health - Trochlear dysplasia.
  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692396.001).
  • [ISSN] 0968-0160
  • [Journal-full-title] The Knee
  • [ISO-abbreviation] Knee
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Wu CC, Chen YS, Chen PJ, Hsu CJ: Common clinical features of children with enlarged vestibular aqueduct and Mondini dysplasia. Laryngoscope; 2005 Jan;115(1):132-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common clinical features of children with enlarged vestibular aqueduct and Mondini dysplasia.
  • The most common malformations were enlarged vestibular aqueduct, incomplete partition of cochlea (Mondini dysplasia), large vestibule, and semicircular canal dysplasia, presenting either as isolated finding or in combination.
  • Eighty-four (74%) ears had abnormalities confined to these four malformations; only 30 (26%) ears showed other malformations.
  • Patients with complex of enlarged vestibular aqueduct, Mondini dysplasia, large vestibule, and semicircular canal dysplasia (EMVS complex) demonstrated a significantly higher incidence of fluctuating hearing loss (93%) and a better hearing level compared with those with other malformations.

  • Genetic Alliance. consumer health - Mondini Dysplasia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15630381.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A, Roychoudhury S, Panda CK: Alterations of ROBO1/DUTT1 and ROBO2 loci in early dysplastic lesions of head and neck: clinical and prognostic implications. Hum Genet; 2009 Mar;125(2):189-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations of ROBO1/DUTT1 and ROBO2 loci in early dysplastic lesions of head and neck: clinical and prognostic implications.
  • Deletion of chromosomal 3p12.3 was suggested to be associated with dysplastic lesions of head and neck.
  • A collection of 72 dysplastic lesions and 116 HNSCC samples and two oral cancer cell lines were analyzed for ROBO1/DUTT1 and ROBO2 deletion and promoter methylation.
  • In mild dysplastic lesions both of these genes showed high molecular alterations and remained more or less constant in subsequent stages.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2001 Mar 9;291(5510):1928-38 [11239147.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3020-8 [12082532.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cell. 2001 Oct 19;107(2):209-21 [11672528.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1019-27 [18270976.001]
  • [Cites] Curr Opin Genet Dev. 2002 Oct;12(5):583-91 [12200164.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] J Clin Pathol. 2006 May;59(5):445-53 [16644882.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • [Cites] Cell. 1999 Mar 19;96(6):795-806 [10102268.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6915-35 [12362274.001]
  • [Cites] Mol Biol (Mosk). 2004 Jul-Aug;38(4):654-67 [15456137.001]
  • [Cites] Laryngoscope. 1999 Oct;109(10):1544-51 [10522920.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):6-15 [11755815.001]
  • [Cites] Neuron. 2004 Apr 22;42(2):213-23 [15091338.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6643-51 [17121883.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Sep;2(3):231-8 [1981839.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3058-64 [12912957.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3257-64 [16740745.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8191-201 [16940181.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Jun;22(2):289-97 [12866580.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2182-9 [10232606.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):676-91 [16607615.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6432-7 [15374951.001]
  • [Cites] Oncogene. 1998 Oct 1;17(13):1723-9 [9796701.001]
  • [Cites] Science. 2001 Apr 20;292(5516):507-10 [11313496.001]
  • [Cites] Oncogene. 1995 Nov 16;11(10):1997-2004 [7478518.001]
  • (PMID = 19104841.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / RNA, Untranslated; 0 / ROBO2 protein, human; 0 / Receptors, Immunologic; 0 / roundabout protein
  •  go-up   go-down


86. de Sousa FA, Paradella TC, Carvalho YR, Rosa LE: Comparative analysis of cell proliferation ratio in oral lichen planus, epithelial dysplasia and oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal; 2009 Nov;14(11):e563-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of cell proliferation ratio in oral lichen planus, epithelial dysplasia and oral squamous cell carcinoma.
  • AIM: To evaluate the cell proliferation rate in oral lichen planus, comparing it to the rate observed in epithelial dysplasia and oral squamous cell carcinoma, aiming at indications which might indicate the potential for malignant transformation.
  • RESULTS: Positivity for PCNA was observed in 58.33% of oral lichen planus cases, 83.33% of epithelial dysplasia cases and 91.67% of oral squamous cell carcinoma cases.
  • No significant statistical difference between oral lichen planus and epithelial dysplasia (p>0.05) and between the epithelial dysplasia and oral squamous cell carcinoma (p>0.05) was observed.
  • The mean NORs/nucleus in oral lichen planus, epithelial dysplasia and oral squamous cell carcinoma were 1.74+/-0.32, 2.42+/-0.62 e 2.41+/-0.61, respectively.
  • CONCLUSION: Oral lichen planus cell proliferation rate was less than in oral epithelial dysplasia and oral squamous cell carcinoma which might explain the lower malignant transformation rate.


87. Ho KS, Cranston RD: Anal cytology screening in HIV-positive men who have sex with men: what's new and what's now? Curr Opin Infect Dis; 2010 Feb;23(1):21-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: This review will discuss current and future anal cytology screening programs to detect anal dysplasia in HIV-positive men who have sex with men (MSM), in addition to other interventions aimed at early detection of anal cancer in this population.
  • RECENT FINDINGS: Evidence of progression from high-grade anal dysplasia to anal cancer has been recently demonstrated and strengthens the clinical imperative to diagnose and treat this lesion in at-risk populations.
  • SUMMARY: Anal cytology, although sensitive for the detection of any anal dysplastic abnormality, has poor specificity to detect high-grade anal dysplasia.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935419.001).
  • [ISSN] 1473-6527
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


88. Xu PJ, Yan FH, Wang JH, Shan Y, Ji Y, Chen CZ: Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr; 2010 Jul;34(4):506-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
  • OBJECTIVES: To evaluate the diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) for the characterization of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) in cirrhotic liver, compared with contrast material-enhanced magnetic resonance imaging (CE-MRI).
  • When the slightly high SI of lesion with a cutoff ADC ratio less than 0.92 was applied as a criterion, the Az, the sensitivity, the specificity, and the accuracy of DWI for the diagnosis of HCC versus DN were 0.81, 67.50%, 94.74%, and 76.27%, respectively.
  • The corresponding Az, sensitivity, specificity, and accuracy of CE-MRI were 0.70, 82.50%, 57.89%, and 74.58%, respectively.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657216.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


89. Kondakova IV, Cheremisina OV, Kakurina GV, Choĭnzonov EL: [Association of the degree of bronchial epithelial dysplasia to the serum level of non-enzymatic antioxidants]. Klin Lab Diagn; 2007 Dec;(12):23-4, 33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of the degree of bronchial epithelial dysplasia to the serum level of non-enzymatic antioxidants].
  • The serum levels of non-enzymatic antioxidants were studied in patients with chronic nonspecific lung diseases with first-to-third-degree dysplasia of the bronchial epithelium (BE) before and after therapeutic correction.
  • The development of BE dysplastic changes was ascertained to cause a considerable reduction in the content of antioxidant vitamin A.
  • During the therapy contributing to reversal of BE dysplastic alterations, there was an increase in the serum levels of vitamin A and uric acid in patients with simple chronic bronchitis with both first- and second-degree dysplasia.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Chronic Bronchitis.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18228666.001).
  • [ISSN] 0869-2084
  • [Journal-full-title] Klinicheskaia laboratornaia diagnostika
  • [ISO-abbreviation] Klin. Lab. Diagn.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antioxidants; 11103-57-4 / Vitamin A; 268B43MJ25 / Uric Acid
  •  go-up   go-down


90. Shenoy MM, Gopa K, Girisha BS, Pinto J, Shetty V: Ellis-van Creveld Syndrome (chondro-ectodermal dysplasia) in two siblings. Kathmandu Univ Med J (KUMJ); 2008 Apr-Jun;6(2):220-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ellis-van Creveld Syndrome (chondro-ectodermal dysplasia) in two siblings.
  • Two male siblings aged 12 and 15 years (Figure 1) presented with growth retardation, limb abnormalities and, defective teeth and nail since childhood.
  • Clinical picture was suggestive of a diagnosis of Chondroectodermal dysplasia (Ellis van Creveld syndrome).

  • Genetic Alliance. consumer health - Ectodermal Dysplasia.
  • Genetic Alliance. consumer health - Ellis-Van Creveld Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769091.001).
  • [ISSN] 1812-2078
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


91. Morag G, Zalzal P, Liberman B, Safir O, Flint M, Gross AE: Outcome of revision hip arthroplasty in patients with a previous total hip replacement for developmental dysplasia of the hip. J Bone Joint Surg Br; 2005 Aug;87(8):1068-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of revision hip arthroplasty in patients with a previous total hip replacement for developmental dysplasia of the hip.
  • Our aim was to determine if the height of the cup, lateralisation or the abduction angle correlated with functional outcome or survivorship in revision total hip replacement in patients with a previous diagnosis of developmental dysplasia of the hip.

  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049240.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Wierusz-Kozłowska M, Markuszewski J, Wozniak W: [Osteoarthritis secondary to the developmental hip dysplasia-treatment options in young patients]. Chir Narzadow Ruchu Ortop Pol; 2005;70(5):325-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteoarthritis secondary to the developmental hip dysplasia-treatment options in young patients].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617763.001).
  • [Journal-full-title] Chirurgia narzadów ruchu i ortopedia polska
  • [ISO-abbreviation] Chir Narzadow Ruchu Ortop Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 22
  •  go-up   go-down


93. Chu SC, Chiang HK: Monte Carlo simulation of fluorescence spectra of normal and dysplastic cervical tissues for optimizing excitation/receiving arrangements. Appl Spectrosc; 2010 Jul;64(7):708-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monte Carlo simulation of fluorescence spectra of normal and dysplastic cervical tissues for optimizing excitation/receiving arrangements.
  • Our aim was to discriminate cervical tissues at different dysplastic stages.
  • The model combined the structure of multi-layered tissues, tissue optical scattering and absorption parameters, tissue fluorophore concentration, the characteristic fluorescent spectrum of fluorophores, and the excitation and receiving arrangement of the optical fibers.
  • [MeSH-major] Cervix Uteri / chemistry. Cervix Uteri / pathology. Monte Carlo Method. Spectrometry, Fluorescence / methods. Uterine Cervical Dysplasia / chemistry. Uterine Cervical Dysplasia / pathology


94. Vakiani E, Yantiss RK: Pathologic features and biologic importance of colorectal serrated polyps. Adv Anat Pathol; 2009 Mar;16(2):79-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serrated polyps of the large intestine comprise a heterogeneous group of mucosal lesions that includes nondysplastic polyps, such as hyperplastic polyps and sessile serrated polyps, and polyps that show overt cytologic dysplasia, namely serrated adenomas and mixed hyperplastic/adenomatous polyps.
  • Several investigators have proposed the concept of the "serrated neoplastic pathway" according to which nondysplastic serrated lesions develop progressively severe dysplasia culminating in the development of microsatellite unstable carcinomas that show DNA hypermethylation and BRAF mutations.
  • A subset of hyperplastic polyps and sessile serrated polyps show mutations in the BRAF gene and abnormal DNA methylation, which can, ultimately, affect the promoter regions of key DNA-repair and tumor suppressor genes, such as MLH1 and MGMT, leading to their decreased transcription and microsatellite instability.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Adv Anat Pathol. 2009 Sep;16(5):360-3
  • (PMID = 19550369.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 97
  •  go-up   go-down


95. McLaughlin SD, Clark SK, Thomas-Gibson S, Tekkis PP, Ciclitira PJ, Nicholls RJ: Guide to endoscopy of the ileo-anal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. Inflamm Bowel Dis; 2009 Aug;15(8):1256-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk of developing dysplasia following RPC is low.
  • Surveillance pouchoscopy is only recommended in those with FAP, those with a previous history of dysplasia or carcinoma, primary sclerosing cholangitis, those with a retained rectal cuff, and those with Type C histological changes.

  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180580.001).
  • [ISSN] 1536-4844
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


96. Balsitis S, Dick F, Dyson N, Lambert PF: Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res; 2006 Oct 1;66(19):9393-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • E7 expression in estrogen-treated murine cervix induced dysplasia and invasive cancers as reported previously, but targeted Rb inactivation in cervical epithelium was not sufficient to induce any cervical dysplasia or neoplasia.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 May;20(10):3715-27 [10779361.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9534-41 [10734102.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3037-50 [11114892.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3051-64 [11114893.001]
  • [Cites] J Virol. 2001 Aug;75(15):6737-47 [11435552.001]
  • [Cites] J Virol. 2001 Aug;75(16):7583-91 [11462030.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7888-98 [11753671.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2923-30 [11713253.001]
  • [Cites] J Virol. 2002 Oct;76(20):10559-68 [12239337.001]
  • [Cites] Nature. 2003 Jul 10;424(6945):223-8 [12853964.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] J Virol. 2003 Oct;77(19):10566-74 [12970441.001]
  • [Cites] J Virol. 2003 Nov;77(22):12331-5 [14581569.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9094-103 [14645521.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8173-80 [14678972.001]
  • [Cites] Development. 2004 Jun;131(11):2737-48 [15148303.001]
  • [Cites] J Virol. 2004 Nov;78(21):11451-60 [15479788.001]
  • [Cites] J Gen Virol. 1985 Jul;66 ( Pt 7):1515-22 [2991428.001]
  • [Cites] J Virol. 1991 Dec;65(12):6922-30 [1834862.001]
  • [Cites] J Virol. 1992 Mar;66(3):1329-35 [1310752.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4549-53 [1316611.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Cell. 1993 Sep 10;74(5):813-22 [8374952.001]
  • [Cites] EMBO J. 1994 Feb 15;13(4):871-8 [8112300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4382-6 [8183918.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5320-4 [8202487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1654-8 [7878034.001]
  • [Cites] Genes Dev. 1995 Oct 1;9(19):2335-49 [7557386.001]
  • [Cites] J Virol. 1996 Mar;70(3):1873-81 [8627712.001]
  • [Cites] EMBO J. 1996 Apr 15;15(8):1950-60 [8617242.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):1888-901 [8634980.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4620-4 [8840974.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] J Virol. 1997 Apr;71(4):2905-12 [9060648.001]
  • [Cites] J Virol. 1997 Aug;71(8):5905-14 [9223480.001]
  • [Cites] J Gen Virol. 1997 Oct;78 ( Pt 10):2607-13 [9349482.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2290-5 [9482878.001]
  • [Cites] Nature. 1998 Feb 26;391(6670):859-65 [9495340.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1599-609 [9620848.001]
  • [Cites] Trends Genet. 1998 Jun;14(6):223-9 [9635405.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1291-6 [9990017.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):744-54 [15599852.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S25-33 [15753009.001]
  • [Cites] J Infect Dis. 2005 Jun 1;191(11):1796-807 [15871111.001]
  • [Cites] J Virol. 2005 Sep;79(17):11392-402 [16103190.001]
  • [Cites] Mol Cell Biol. 2006 May;26(9):3659-71 [16612004.001]
  • [Cites] J Virol. 2000 Jul;74(14):6622-31 [10864676.001]
  • (PMID = 17018593.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098428-05; United States / NCI NIH HHS / CA / P30 CA014520; United States / NIGMS NIH HHS / GM / T32 GM00721; United States / NCI NIH HHS / CA / CA098428; United States / NCI NIH HHS / CA / CA098428-05; United States / NCI NIH HHS / CA / CA64402; United States / NCI NIH HHS / CA / R01 CA064402; United States / NCI NIH HHS / CA / P01 CA022443-310006; United States / NCI NIH HHS / CA / CA022443-310006; United States / NCI NIH HHS / CA / R01 CA098428-06; United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / R01 CA098428; United States / NCI NIH HHS / CA / CA22443
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / DNA-Binding Proteins; 0 / Estrogens; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; EC 3.6.4.12 / Mcm7 protein, mouse; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 7
  • [Other-IDs] NLM/ NIHMS193057; NLM/ PMC2858286
  •  go-up   go-down


97. Wang JS, Varro A, Lightdale CJ, Lertkowit N, Slack KN, Fingerhood ML, Tsai WY, Wang TC, Abrams JA: Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol; 2010 May;105(5):1039-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We decided to investigate the association between serum gastrin levels and dysplasia in BE.
  • METHODS: We performed a cross-sectional study and enrolled patients with BE without dysplasia, low-grade dysplasia (LGD), high-grade dysplasia (HGD), or adenocarcinoma (AC), as well as gastroesophageal reflux disease controls, all chronically taking PPIs.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Invest. 1992 Oct;22(10):638-44 [1459168.001]
  • [Cites] Gastroenterology. 1990 Oct;99(4):918-22 [2394347.001]
  • [Cites] N Engl J Med. 1995 Oct 26;333(17):1106-10 [7565948.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] Gastroenterology. 1997 Mar;112(3):707-17 [9041231.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Gastroenterology. 1998 Aug;115(2):275-80 [9679032.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):327-35 [10419913.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):288-93 [16492917.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):15-29 [16054292.001]
  • [Cites] Gut. 2006 Nov;55(11):1538-44 [16785284.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Nov 1;24(9):1321-31 [17059513.001]
  • [Cites] Digestion. 2006;74(1):42-6 [17068397.001]
  • [Cites] Am J Gastroenterol. 2007 Jan;102(1):10-20 [17266684.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Mar 15;25(6):715-22 [17311605.001]
  • [Cites] BMC Gastroenterol. 2007;7:24 [17597535.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):755-60 [17678921.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):748-54 [17678926.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8580-7 [17875697.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Feb 15;27(4):321-6 [18047565.001]
  • [Cites] Gut. 2008 Mar;57(3):281-4 [18268049.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):1070-82 [18395088.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Aug 15;28(4):491-6 [18557987.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):487-96 [10702199.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5767-72 [11059772.001]
  • [Cites] Gut. 2001 Mar;48(3):304-9 [11171817.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):990-6 [11316217.001]
  • [Cites] Oncogene. 2001 Nov 29;20(55):7987-91 [11753681.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):422-9 [11904314.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):60-7 [12105834.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):615-25 [12612900.001]
  • [Cites] Pharmacogenomics. 2004 Mar;5(2):181-202 [15016609.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1915-9 [15026323.001]
  • [Cites] Am J Gastroenterol. 2004 Feb;99(2):218-24 [15046208.001]
  • [Cites] Regul Pept. 2004 Aug 15;120(1-3):195-203 [15177938.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4784-92 [15269153.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G743-8 [15231484.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1877-83 [15447744.001]
  • [Cites] Gastroenterology. 1990 Sep;99(3):621-8 [2199288.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):907-15 [7848395.001]
  • (PMID = 19904251.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / ; United States / NCI NIH HHS / CA / K07 CA132892-04; United States / NIDDK NIH HHS / DK / R01 DK52778; United States / NIDDK NIH HHS / DK / R37 DK052778; United States / NIDDK NIH HHS / DK / R01 DK052778; United States / NCI NIH HHS / CA / K07 CA132892; United Kingdom / Medical Research Council / / G9900432
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gastrins; 0 / Proton Pump Inhibitors
  • [Other-IDs] NLM/ NIHMS307177; NLM/ PMC3139948
  •  go-up   go-down


98. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X: MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res; 2009 Sep 15;15(18):5744-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: In this study, we analyzed the expression patterns of 470 human miRNAs using Agilent miRNA microarray in 32 disease/normal-paired tissues from 16 patients diagnosed with Barrett's esophagus of either low- or high-grade dysplasia, or esophageal adenocarcinoma.
  • RESULTS: Using unsupervised hierarchical clustering and class comparison analyses, we found that miRNA expression profiles in tissues of Barrett's esophagus with high-grade dysplasia were significantly different from their corresponding normal tissues.
  • Similar findings were observed for esophageal adenocarcinoma, but not for Barrett's esophagus with low-grade dysplasia.
  • Finally, we identified several miRNAs that were involved in the progressions from low grade-dysplasia Barrett's esophagus to esophageal adenocarcinoma.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Dec 15;98(12):2740-1 [14669301.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2448-55 [14668230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Mol Carcinog. 1995 Dec;14(4):286-93 [8519418.001]
  • [Cites] Am J Gastroenterol. 1998 Jun;93(6):911-5 [9647017.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):226-30 [15538371.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):259-67 [16344314.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):283-9 [16421561.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):228-33 [16380711.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2537-45 [16331254.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]
  • [Cites] RNA. 2007 Jan;13(1):151-9 [17105992.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):976-83 [17283129.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):912-9 [17289885.001]
  • [Cites] Cell. 2007 Apr 6;129(1):147-61 [17382377.001]
  • [Cites] Nat Genet. 2007 May;39(5):582-3 [17460676.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] Nat Med. 2007 May;13(5):613-8 [17468766.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4553-5 [17510380.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):26-33 [18172293.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Feb;135(2):255-60; discussion 260 [18242245.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2690-5 [18451233.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Brain Res. 2008 Oct 21;1236:185-93 [18710654.001]
  • [Cites] J Am Coll Surg. 2000 May;190(5):562-72; discussion 572-3 [10801023.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jun;12(6):649-54 [10912484.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Jul;15(7):730-6 [10937677.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • (PMID = 19737949.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA111922-02; United States / NCI NIH HHS / CA / R01 CA111922; United States / NCI NIH HHS / CA / CA111922; United States / NCI NIH HHS / CA / R01 CA111922-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS125002; NLM/ PMC2745487
  •  go-up   go-down


99. Sokolov VV, Gladyshev AA, Telegina LV, Filonenko EV, Reshetov IG, Golubtsov AK, Frank GA, Belous TA, Zavalishina LE: [Combined endolaryngeal videoendoscopic surgery and photodynamic treatment of patients with recurrent laryngeal and tracheal papillomatosis]. Vestn Otorinolaringol; 2007;(6):4-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell papilloma was accompanied with dysplasia of the first-second degree in 10 (31%) patients, dysplasia of the third degree - in 4 (12,5%), cancer in situ - in 3 (9,4%) patients.
  • In patients with dysplasia of degree I-III and cancer in situ (n=17) CR of dysplasia and preinvasive cancer foci was achieved in 15 (88%) patients.

  • Genetic Alliance. consumer health - Laryngeal papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18163084.001).
  • [ISSN] 0042-4668
  • [Journal-full-title] Vestnik otorinolaringologii
  • [ISO-abbreviation] Vestn. Otorinolaringol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 37
  •  go-up   go-down


100. Yokoyama A, Mizukami T, Omori T, Yokoyama T, Hirota T, Matsushita S, Higuchi S, Maruyama K, Ishii H, Hibi T: Melanosis and squamous cell neoplasms of the upper aerodigestive tract in Japanese alcoholic men. Cancer Sci; 2006 Sep;97(9):905-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanosis is frequently observed in the upper aerodigestive tract of Japanese alcoholic men, and the prevalences of squamous cell dysplasia and SCC in the upper aerodigestive tract of Japanese alcoholic men are high.
  • The incidence of melanosis was higher in those with esophageal dysplasia (31/126, 24.6%), esophageal SCC (19/42, 45.2%), and oropharyngolaryngeal SCC (8/14, 54.1%) than in cancer- and dysplasia-free controls (69/437, 15.8%).
  • The presence of melanosis was associated with a higher risk of esophageal dysplasia, esophageal SCC, and oropharyngolaryngeal SCC (OR 1.69, 4.03, and 6.61, respectively).






Advertisement